<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>ema-combined-h2246en - with comments</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
span.MsoFootnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.CCDSMandatoryInformationbullet, li.CCDSMandatoryInformationbullet, div.CCDSMandatoryInformationbullet
	{mso-style-name:"CCDS Mandatory Information bullet";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.Listenabsatz1, li.Listenabsatz1, div.Listenabsatz1
	{mso-style-name:Listenabsatz1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Listenabsatz1CxSpFirst, li.Listenabsatz1CxSpFirst, div.Listenabsatz1CxSpFirst
	{mso-style-name:Listenabsatz1CxSpFirst;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Listenabsatz1CxSpMiddle, li.Listenabsatz1CxSpMiddle, div.Listenabsatz1CxSpMiddle
	{mso-style-name:Listenabsatz1CxSpMiddle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Listenabsatz1CxSpLast, li.Listenabsatz1CxSpLast, div.Listenabsatz1CxSpLast
	{mso-style-name:Listenabsatz1CxSpLast;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Helvetica",sans-serif;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><i> <span lang=EN-GB>                                                                                                         </span></i></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<i><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></i>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img width=21
height=18 id="Picture 1" src="NexoBrid_files/image001.gif" alt="BT_1000x858px"></span><span
lang=EN-GB> This medicinal product is subject to additional monitoring. This
will allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions. See section
4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid 2&nbsp;g
powder and gel for gel</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>2.       QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial
contains 2&nbsp;g of </span>concentrate of <span lang=EN-GB>proteolytic enzymes
enriched in bromelain, corresponding to 0.09&nbsp;g/g concentrate of proteolytic
enzymes enriched in bromelain after mixing (or 2&nbsp;g/22&nbsp;g gel).</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'>&nbsp;</p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'>The proteolytic enzymes are a mixture of enzymes from the
stem of <i>Ananas comosus</i> (pineapple plant).</p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=EMEAEnBodyText style='margin:0in;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText style='margin:0in;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and gel
for gel.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The powder is off-white to light tan. The gel is clear and
colourless.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.       Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid is
indicated for removal of eschar in adults with deep partial- and full-thickness
thermal burns<i>.</i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.2<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid should only
be applied by trained healthcare professionals in specialist burn centres.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span
 lang=EN-GB>2&nbsp;g</span><span lang=EN-GB> NexoBrid powder in 20&nbsp;g gel
is applied to a burn wound area of 100&nbsp;cm<sup>2</sup>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid should
not be applied to more than 15%&nbsp;Total Body Surface Area (TBSA) (see also section
4.4,<i> </i>Coagulopathy).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid should
be left in contact with the burn for a duration of 4&nbsp;hours. There is very limited
information on the use of NexoBrid on areas where eschar remained after the
first application.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A second and
subsequent application is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
information on the use of NexoBrid in patients with renal impairment. These
patients should be carefully monitored.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
information on the use of NexoBrid in patients with hepatic impairment.  These patients
should be carefully monitored.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly
patients</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Experience with
NexoBrid in elderly patients (&gt;65&nbsp;years) is limited. Benefit/risk
assessment should include consideration of the greater frequency of concomitant
disease or other medicinal product therapy in the elderly. No dose adjustment
is required.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of NexoBrid in children and adolescents younger than 18&nbsp;years
have not yet been established. Currently available data are described in
section 4.8 and 5.1 but no recommendation on a posology can be made.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid is not
indicated for use in patients younger than 18&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Before use, the
powder must be mixed with the gel producing a uniform gel.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>NexoBrid should be applied to a clean, keratin-free
(blisters removed), and moist wound area.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Topically
applied medicinal products (such as silver sulfadiazine or povidone-iodine) at
the wound site must be removed and the wound must be cleansed prior to NexoBrid
application.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>See section 6.6
for instructions on NexoBrid gel preparation.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Preparation
of patient and wound area</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A total wound
area of not more than 15%&nbsp;TBSA can be treated with NexoBrid (see also
section 4.4,<i> </i>Coagulopathy).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain management must be used as commonly practiced
for an extensive dressing change; it should be initiated at least
15&nbsp;minutes prior to NexoBrid application.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must be cleaned thoroughly and the
superficial keratin layer or blisters removed from the wound area, as the
keratin will isolate the eschar from direct contact with NexoBrid and prevent
eschar removal by NexoBrid.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dressing soaked with an antibacterial solution must
be applied for 2&nbsp;hours.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>All topically applied antibacterial medicinal
products must be removed before applying NexoBrid. Remaining antibacterial medicinal
products may interfere with the activity of NexoBrid by decreasing its
efficacy.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The area from which you wish to remove the
eschar must be surrounded with a sterile paraffin ointment adhesive barrier by applying
it a few centimetres outside of the treatment area (using a dispenser). The
paraffin layer must not come into contact with the area to be treated to avoid
covering the eschar, thus isolating the eschar from direct contact with
NexoBrid.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>To prevent possible irritation of abraded skin by inadvertent
contact with NexoBrid and possible bleeding from the wound bed, acute wound
areas such as lacerations or escharotomy incisions should be protected by a
layer of a sterile fatty ointment or fatty dressing (e.g. petrolatum gauze)..</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Sterile isotonic sodium chloride 9&nbsp;mg/ml
(0.9%) solution must be sprinkled on the burn wound. The wound must be kept
moist during the application procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>NexoBrid
application</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Within 15&nbsp;minutes of mixing, NexoBrid must be
applied topically to the moistened burn wound, at a thickness of 1.5 to
3&nbsp;millimetres.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must then be covered with a sterile
occlusive film dressing that adheres to the sterile adhesive barrier material
applied as per the instruction above (see <i>Preparation of patient and wound
area</i>). The NexoBrid gel must fill the entire occlusive dressing, and
special care should be taken not to leave air under this occlusive dressing.
Gentle pressing of the occlusive dressing at the area of contact with the
adhesive barrier will ensure adherence between the occlusive film and the
sterile adhesive barrier and achieve complete containment of NexoBrid on the
treatment area.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dressed wound must be covered with a loose,
thick fluffy dressing, held in place with a bandage.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dressing must remain in place for
4&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Removal of
NexoBrid</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Appropriate preventive analgesia medicinal
products must be administered.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>After 4&nbsp;hours of NexoBrid treatment, the
occlusive dressing must be removed using aseptic techniques.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The adhesive barrier must be removed using a
sterile blunt-edged instrument (e.g., tongue depressor).</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dissolved eschar must be removed from the
wound by wiping it away with a sterile blunt-edged instrument.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must be wiped thoroughly first with a
large sterile dry gauze or napkin, followed by a sterile gauze or napkin that
has been soaked with sterile isotonic sodium chloride 9 mg/ml (0.9%) solution. The
treated area must be rubbed until the appearance of a pinkish surface with
bleeding points or a whitish tissue. Rubbing will not remove adhering
undissolved eschar in areas where the eschar still remains.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A dressing soaked with an antibacterial solution
must be applied for an additional 2&nbsp;hours.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Wound care
after debridement</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The debrided area must be covered immediately by
temporary or permanent skin substitutes or dressings to prevent desiccation
and/or formation of pseudoeschar and/or infection.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Before a permanent skin cover or temporary skin
substitute is applied to a freshly enzymatically debrided area, a soaking
wet-to-dry dressing must be applied. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Before application of the grafts or primary
dressing, the debrided bed must be cleaned and refreshed by, e.g., brushing or
scraping to allow dressing adherence.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Wounds with areas of full-thickness and deep burn
should be autografted as soon as possible after NexoBrid debridement. Careful
consideration should also be given to placing permanent skin covers (e.g.
autografts) on deep partial thickness wounds soon after NexoBrid debridement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>          See
section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each NexoBrid
vial, gel, or reconstituted gel should be used for a single patient only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;text-align:justify;line-height:
normal'><span lang=EN-GB>Hypersensitivity to the active substance, to
pineapples or papain (see also section 4.4), or to any of the excipients listed
in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concentrate of
proteolytic enzymes enriched in bromelain is systemically absorbed from burn
wound areas (see section 5.2).</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>NexoBrid is not recommended for use on:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:1.3pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>penetrating burn wounds where foreign materials
(e.g. implants, pacemakers, and shunts) and<span style='color:black'>/ or vital
structures (e.g. larger vessels, eyes) are or could become exposed during
debridement</span>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:1.3pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chemical burn wounds.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:1.3pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>wounds contaminated with
radioactive and other hazardous substances to avoid unforeseeable reactions
with the product and an increased risk of spreading the noxious substance.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Use in patients with cardiopulmonary and pulmonary disease</span></u></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><span
lang=EN-GB>NexoBrid should be used with caution in patients with<u> </u>cardiopulmonary
and pulmonary disease, including pulmonary burn trauma and suspected pulmonary
burn trauma.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><span
lang=EN-GB>General principles of proper burn wound care must be adhered to when
using NexoBrid. This includes proper wound cover for the exposed tissue.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Burns for which there is limited or no experience</span></u></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
experience of the use of NexoBrid on:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:1.3pt;margin-bottom:0in;
margin-left:28.1pt;margin-bottom:.0001pt;text-indent:-28.1pt;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>perineal and genital burns.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:1.3pt;margin-bottom:0in;
margin-left:28.1pt;margin-bottom:.0001pt;text-indent:-28.1pt;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>electrical burns.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is limited
information on the use of NexoBrid on facial burn wounds.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;line-height:normal'><span
lang=EN-GB>NexoBrid must be used with caution in such patients. Eyes should be
carefully protected during treatment of facial burns using adhesive barrier
petroleum ointment. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><span
lang=EN-GB>There is limited pharmacokinetic data in patients with TBSA of more
than 15%. Due to safety considerations (see also section 4.4,<i> </i>Coagulopathy)
NexoBrid should not be applied to more than 15%Total Body Surface Area (TBSA).</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Prevention of wound complications</span></u></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In NexoBrid
studies wounds with visible dermal remnants were allowed to heal by spontaneous
epithelialisation. In several cases adequate healing did not occur and
autografting was required at a later date, leading to significant delays in
wound closure which is associated with increased risk of wound-related
complications. Therefore, wounds with areas of full-thickness and deep burn
should be autografted as soon as possible after NexoBrid debridement (see
section 5.1 for study results). Careful consideration should also be given to
placing permanent skin covers (e.g. autografts) on deep partial thickness
wounds soon after NexoBrid debridement. See also section 4.2 and 4.8.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;line-height:normal'><span
lang=EN-GB>As in the case of surgically debrided bed, in order to prevent
desiccation and/or formation of pseudoeschar and/or infection, the debrided
area should be covered immediately by temporary or permanent skin substitutes
or dressings. When applying a permanent skin cover (e.g., autograft) or
temporary skin substitute (e.g., allograft) to a freshly enzymatically debrided
area, care should be taken to clean and refresh the debrided bed by, e.g.,
brushing or scraping to allow dressing adherence.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Eye protection</span></u></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>Direct contact with the eyes should be avoided. If there is a risk
of eye contact, the patients eyes should be protected with fatty ophthalmic
ointment.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>In case of eye exposure, irrigate exposed eyes with copious amounts
of water for at least 15&nbsp;minutes. </span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Hypersensitivity reactions, skin exposure</span></u></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:7.0pt;
margin-left:.1pt;line-height:14.0pt;background:white;text-autospace:none'><span
lang=EN-GB style='color:black'>There have been reports of serious allergic
reactions including anaphylaxis (with manifestations such as rash, erythema,
hypotension, tachycardia) in patients undergoing debridement with NexoBrid. </span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Allergic reactions to bromelain have been reported in
the literature (including anaphylactic reactions and other immediate-type
reactions with manifestations such as bronchospasm, angiooedema, urticaria, and
mucosal and gastrointestinal reactions). In addition, a delayed-type allergic
skin reaction (cheilitis) after longer-term dermal exposure (mouthwash) as well
as suspected sensitisation following oral exposure and following repeated
occupational airway exposure have been reported. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>                                                                                                                </span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>The potential of NexoBrid (a protein product) to cause sensitisation
should be taken into account when re-exposing patients to bromelain-containing
products at a later point in time. The use of NexoBrid in subsequent burn
injury is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>In case of skin exposure, NexoBrid should be rinsed off
with water to reduce the likelihood of skin sensitisation (see section 6.6).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Cross-sensitivity</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Cross-sensitivity between bromelain and papain as well
as latex proteins (known as latex-fruit syndrome), bee venom, and olive tree
pollen has been reported in the literature.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Coagulopathy</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>It is not known if NexoBrid application has any clinically relevant
effect on haemostasis.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>An increase in heart rate (including tachycardia), reduction of
platelet aggregation and plasma fibrinogen levels and a moderate increase in
partial thromboplastin and prothrombin times have been reported in the
literature as possible effects following oral administration of bromelain. <i>In
vitro</i> and animal data suggest that bromelain can also promote fibrinolysis.
During the clinical development of NexoBrid, there was no indication of an
increased bleeding tendency or bleeding at the site of debridement. </span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>NexoBrid should be used with caution in patients with disorders of
coagulation, low platelet counts and increased risk of bleeding from other
causes e.g. peptic ulcers and sepsis.</span></p>

<p class=Listenabsatz1 style='margin-left:0in;text-align:justify;line-height:
normal'><span lang=EN-GB>Patients should be monitored for possible signs of
coagulation abnormalities.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Monitoring</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In addition to routine monitoring for burn patients (e.g., vital
signs, volume/water/electrolyte status, complete blood count, serum albumin and
hepatic enzyme levels), patients treated with NexoBrid should be monitored for:</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rise in body temperature. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Signs of local and systemic inflammatory and
infectious processes. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Conditions that could be precipitated or
worsened by analgesic premedication (e.g., gastric dilatation, nausea and risk
of sudden vomiting, constipation) or antibiotic prophylaxis (e.g., diarrhoea). </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Signs of local or systemic allergic reactions.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Potential effects on haemostasis (see above).</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;line-height:normal'><i><s><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></i></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Removal of topically applied antibacterial medicinal products before
NexoBrid application</span></u></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><span
lang=EN-GB>All topically applied antibacterial medicinal products must be
removed before applying NexoBrid. Remaining antibacterial medicinal products may
interfere with the activity of NexoBrid by decreasing its efficacy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5     Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies with NexoBrid have been performed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reduction of platelet aggregation and plasma fibrinogen levels and a
moderate increase in partial thromboplastin and prothrombin times have been
reported as possible effects following oral administration of bromelain. </span><i><span
lang=EN-GB>In vitro</span></i><span lang=EN-GB> and animal data suggest that
bromelain can also promote fibrinolysis. Caution and monitoring is therefore
needed when prescribing concomitant medicinal products that affect coagulation.
See also section 4.4.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>NexoBrid, when absorbed, is an inhibitor of cytochrome P 450 2C8
(CYP2C8) and P450 2C9 (CYP2C9). This should be taken into account if NexoBrid
is used in patients receiving CYP2C8 substrates (including amiodarone,
amodiaquine, chloroquine, fluvastatin, paclitaxel, pioglitazone, repaglinide,
rosiglitazone, sorafenib and torasemide) and CYP2C9 substrates (including </span><span
lang=EN-GB>ibuprofen, tolbutamide, glipizide, losartan, celecoxib, warfarin,
and phenytoin). </span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Topically applied antibacterial medicinal products (e.g. silver
sulfadiazine or povidone iodine) may decrease the efficacy of NexoBrid (see
section 4.4).</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Bromelain
may enhance the actions of fluorouracil and vincristine. Patients should be
monitored for increased toxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-GB>Bromelain
may enhance the hypotensive effect of ACE inhibitors, causing larger decreases
in blood pressure than expected. Blood pressure should be monitored in patients
receiving ACE inhibitors </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-GB>Bromelain
may increase drowsiness caused by some medicinal products (e.g., benzodiazepines,
barbiturates, narcotics and antidepressants). This should be taken into account
when dosing such products.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6     </span></b><b><span lang=EN-GB>Fertility, p</span></b><b><span
lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in'><span lang=EN-GB>There
are no data from the use of NexoBrid in pregnant women.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Animal studies are insufficient to properly assess the potential of
NexoBrid to interfere with embryonal/foetal development (see section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Since the safe
use of NexoBrid during pregnancy has not yet been established, NexoBrid is not
recommended during pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is unknown
whether concentrate of proteolytic enzymes enriched in bromelain or its metabolites
are excreted in human milk. A risk to newborns/infants cannot be excluded.
Breast-feeding should be discontinued at least 4&nbsp;days from  NexoBrid
application initiation.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No studies were
performed to assess the effects of NexoBrid on fertility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7     Effects on ability to drive and use
machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not relevant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.8<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The most commonly reported adverse reactions of the use of NexoBrid
are local pain and transient pyrexia/hyperthermia. When NexoBrid was used in a
regimen which included recommended preventive analgesia as routinely practiced
for extensive dressing changes in burn patients as well as antibacterial soaking
of the treatment area before and after NexoBrid application (see section 4.2), pain
was reported in 3.6% of patients, pyrexia/hyperthermia in 19.1% of patients.
The frequency of pain and pyrexia/hyperthermia was higher without these
precautionary measures (see below).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The following definitions apply to the frequency terminology used
hereafter:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very common (&#8805;1/10)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Common (&#8805;1/100 to &lt;1/10)</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Uncommon (</span><span lang=EN-GB
style='font-family:Symbol'>³</span><span lang=EN-GB>1/1,000 to &lt;1/100)</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Rare (</span><span lang=EN-GB
style='font-family:Symbol'>³</span><span lang=EN-GB>1/10,000 to &lt;1/1,000)</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Very rare (&lt;1/10,000)</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Not known (cannot be estimated from the available data).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The frequencies of the adverse reactions presented below reflect the
use of NexoBrid to remove eschar from deep partial- or full-thickness burns in
a regimen with local antibacterial prophylaxis, recommended analgesia, as well
as coverage of the wound area after application of NexoBrid for 4&nbsp;hours
with an occlusive dressing for containment of NexoBrid on the wound.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>An asterisk (*) indicates that additional information on the
respective adverse reaction is provided below the list of adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Infections and infestations</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Common:             Wound infection</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Skin and subcutaneous tissue disorders/ </span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Common:             Wound complication*</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>General disorders and administration site conditions</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very common:      Pyrexia/hyperthermia* </span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-85.05pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>Common:             Local pain* </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Immune system disorders</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Not known:          Serious allergic reactions including anaphylaxis
</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Pyrexia/hyperthermia</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In studies implementing routine antibacterial soaking of the
treatment area before and after NexoBrid application (see section 4.2)</span><span
lang=EN-GB> pyrexia or hyperthermia was reported in 19.1% of patients treated
with NexoBrid and in 15.8% of the control patients treated according standard
of care. In the NexoBrid group, the event was graded as mild, moderate or
severe in 9.1%, 9.1%, and 0% of patients, respectively.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In studies without antibacterial soaking, pyrexia or hyperthermia
was reported in 35.6% of NexoBrid-treated patients compared with 18.6% in
control patients. In the NexoBrid group, the event was graded as mild, moderate
or severe in 30.0%, 5.6% and 1.1% of patients, respectively.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Pain</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In studies where the NexoBrid regimen included recommended
preventive analgesia as routinely practiced for extensive dressing changes in
burn patients (see section 4.2) </span><span lang=EN-GB>local pain was reported
in 3.6% of patients treated with NexoBrid and in 4.0% of the control patients
treated according to standard of care. In the NexoBrid group, the event was
graded as mild, moderate or severe in 0.9%, 0.9%, and 1.8% of patients,
respectively.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In studies where analgesia was provided in NexoBrid-treated patients
on an on-demand basis, </span><span lang=EN-GB>local pain was reported in 23.3%
of patients treated with NexoBrid and in 11.4% of the control patients. In the
NexoBrid group, the event was graded as mild, moderate or severe in 6.7%, 7.8%
and 8.9% of patients, respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Wound
complications</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In phase 2 and phase 3 clinical studies,
certain types of wound complications were reported more frequently in the
NexoBrid group than in the group treated according to the study sites Standard
of Care (SOC)<span style='color:#00B050'>. </span>These events included: wound
deepening or desiccation (decomposition) in 5 patients (2.4%) with NexoBrid and
0 with SOC as well as (partial) graft failure in 6 patients (2.9%) with
NexoBrid and 2 (1.6%) with SOC (see section 4.4).</span></p>

<p class=Listenabsatz1 style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>General infections</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In phase 2 and phase 3 clinical studies general infections (not
wound related. e.g. urinary tract infections, viral infections) were reported
more frequently in the NexoBrid group (0.147 events per patient) than in the group
treated according to SOC (0.079 events per patient).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There is only limited safety data from the use in the paediatric
population. From these data it is expected that the overall safety profile in
children 4&nbsp;years of age and older and in adolescents is similar to the
profile in adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with </span>concentrate
of <span lang=EN-GB>proteolytic enzymes enriched in bromelain </span><span
lang=EN-GB>prepared in a powder:gel ratio of 1:5 (0.16g per g of mixed gel) in
patients with deep partial- and/or full-thickness burns within the framework of
a clinical study did not result in significantly different safety findings when
compared to treatment with concentrate of proteolytic enzymes enriched in
bromelain prepared in a powder:gel ratio of 1:10 (0.09 g per 1g of mixed gel).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Preparations for treatment of wounds and ulcers, proteolytic enzymes; ATC
code: D03BA03. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Concentrate of proteolytic enzymes </span>enriched in bromelain <span
lang=EN-GB>is a debriding agent, applied topically for removal of eschar in
deep partial- and full-thickness burns. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Mechanism of
action</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The mixture of
enzymes in NexoBrid dissolves burn wound eschar. The specific components
responsible for this effect have not been identified. The major constituent is
stem bromelain.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Clinical efficacy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During clinical
development, a total of 362 patients were treated with the concentrate of
proteolytic enzymes enriched in bromelain. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy of
NexoBrid in humans was evaluated, compared to standard of care, in a
randomised, multi-centre, multi-national, open-label, confirmatory phase 3
study in hospitalised patients with deep partial- and/or full-thickness thermal
burns of 5 to 30% Total Body Surface Area (TBSA), but with total burn wounds of
no more than 30% TBSA.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid
(2&nbsp;g/100&nbsp;cm<sup>2</sup>, corresponding to 0.02&nbsp;g/cm<sup>2</sup>)
was used as described in section 4.2.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Standard of care
consisted of primary surgical excision and/or nonsurgical debridement using
topical medicinal products to induce maceration and autolysis of eschar
according to each study sites standard practice.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The age range in
the group treated with NexoBrid was 4.4 to 55.7&nbsp;years. The age range in
the SOC group was 5.1 to 55.7&nbsp;years. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy of
eschar removal was evaluated by determining the percentage of wound area left
with eschar that required further removal by excision or dermabrasion, and the
percentage of wounds requiring such surgical removal. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effect on
the timing of eschar removal was evaluated in patients with successful eschar
removal (with at least 90% eschar removal in all wounds of a patient combined),
by determining the time from injury as well as from informed consent to
successful removal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The co-primary
endpoints for the efficacy analysis were:</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the percentage of deep partial thickness wounds
requiring excision or dermabrasion, and</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the percentage of deep partial thickness wounds
autografted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This endpoint
can only be evaluated for deep partial-thickness wounds without full-thickness
areas because full-thickness burns always require grafting.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Efficacy data
generated in this study for all age groups combined as well as from a subgroup
analysis for children and adolescents are summarised below. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>NexoBrid</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.05pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>SOC</span></b></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>p-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=555 colspan=4 valign=top style='width:416.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial-thickness wounds requiring excision/dermabrasion (surgery)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>106</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>88</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wounds requiring surgery</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>15.1%</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>62.5%</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area excised or dermabraded<sup>1</sup>
  (mean ± SD) </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>5.5% ± 14.6</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>52.0% ± 44.5</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=555 colspan=4 valign=top style='width:416.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial-thickness wounds autografted</span></b><span lang=EN-GB>*</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>106</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>88</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  % of wounds
  autografted</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>17.9%</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>34.1%</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0099</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area autografted (mean ± SD)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8.4% ± 21.3</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>21.5% ± 34.8</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0054</span></p>
  </td>
 </tr>
 <tr>
  <td width=555 colspan=4 valign=top style='width:416.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial- and/or full-thickness wounds requiring excision/dermabrasion
  (surgery)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>163</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.05pt;text-align:center;
  line-height:normal'><span lang=EN-GB>170</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wounds requiring surgery</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>24.5%</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.05pt;text-align:center;
  line-height:normal'><span lang=EN-GB>70.0%</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area excised or dermabraded<sup>1</sup>
  (mean ± SD) </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>13.1% ± 26.9</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.05pt;text-align:center;
  line-height:normal'><span lang=EN-GB>56.7% ± 43.3</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=555 colspan=4 valign=top style='width:416.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Time to
  complete wound closure (time from ICF**)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  patients<sup>2</sup></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>70</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>78</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  Days to closure of last wound (mean ± SD)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>36.2 ± 18.5</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>28.8 ± 15.6</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0185</span></p>
  </td>
 </tr>
 <tr>
  <td width=555 colspan=4 valign=top style='width:416.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Time to
  successful eschar removal</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  Number of patients</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>67</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>73</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Days (mean ±
  SD) from   injury</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>2.2 ± 1.4</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8.7 ± 5.7</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Days (mean ±
  SD) from   consent</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>0.8 ± 0.8</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.7 ± 5.8</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients not
  reported to have successful eschar removal </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>1</span></sup><span
lang=EN-GB> Measured at first session, if there was more than one surgery
session. <br>
<sup>2</sup> All randomised patients for whom data for complete wound closure
were available. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*The endpoint
can only be evaluated for deep partial-thickness wounds without full-thickness
areas because full-thickness burns always require grafting.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>** Informed
Consent Form</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table shows results in mixed wounds.</span> The comparisons in mixed wounds
should be interpreted with caution since they are based on groups that are not
fully randomized and the mixed wounds treated by NexoBrid were overall larger
and had a larger full thickness area.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Mixed wounds
(with partial and full-thickness area) requiring excision/dermabrasion
(surgery)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>NexoBrid</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(Number of
  wounds)</span></b></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>SOC</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(Number of
  wounds)</span></b></p>
  </td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>% of wounds
  requiring surgery</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>41.7% (20/48)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>78.3% (47/60)</span></p>
  </td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>% of wound
  area excised or dermabraded</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>25.5% (n=48)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>64.0% (n=60)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Mixed wounds
(with partial and full-thickness area) autografted</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>NexoBrid</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(Number of
  wounds)</span></b></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>SOC</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(Number of wounds)</span></b></p>
  </td>
 </tr>
 <tr style='height:21.9pt'>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.9pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>All mixed
  burns baseline characteristics</span></b></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>48 wounds</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.9pt'>
  <p class=MsoNormal style='line-height:normal'>60 wounds</p>
  </td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Size</span></b><span
  lang=EN-GB>: % mean TBSA </span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>7.43</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6.33</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Depth</span></b><span
  lang=EN-GB>: </span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Superficial
  (%TBSA)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.92</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  DPT (% TBSA)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3.85</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3.13</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  FT    (%
  TBSA)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.90</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.29</span></p>
  </td>
 </tr>
 <tr style='height:16.15pt'>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Incidence of
  autograft</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>70.8% (34/48)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>63.3% (38/60) </span></p>
  </td>
 </tr>
 <tr style='height:13.65pt'>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.65pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>% wound area
  autografted </span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.65pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>55.5% (n=48)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.65pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>45.8% (n=60) </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table shows the time to complete wound closure from start of debridement.*</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=532
 style='border-collapse:collapse'>
 <tr style='height:17.5pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Wound Type </span></b></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border:solid black 1.0pt;
  border-left:none;padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB style='color:black'>NexoBrid </span></b></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border:solid black 1.0pt;
  border-left:none;padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB style='color:black'>SOC </span></b></p>
  </td>
 </tr>
 <tr style='height:17.5pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB style='color:black'>Days (mean ± SD)<br>
  (Number of wounds) </span></b></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB style='color:black'>Days (mean ± SD)<br>
  (Number of wounds)</span></b></p>
  </td>
 </tr>
 <tr style='height:19.75pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>All wounds (ITT<sup>1</sup>)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>30.5 ± 16.9<br>
  (154)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>26.1 ± 16.0 <br>
  (164) </span></p>
  </td>
 </tr>
 <tr style='height:19.75pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Non-autografted wounds (ITT)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>23.9 ± 13.0<br>
  (95)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>24.5 ± 14.1<br>
  (85)</span></p>
  </td>
 </tr>
 <tr style='height:19.75pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Autografted wounds (ITT)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>41.0 ± 17.3<br>
  (59)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>27.8 ± 17.7<br>
  (79)</span></p>
  </td>
 </tr>
 <tr style='height:18.15pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:.05in .1in .05in .1in;height:18.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Deep Partial Thickness wounds</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:18.15pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>26.6 ± 15.4<br>
  (101)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:18.15pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>23.7 ± 13.6<br>
  (87)</span></p>
  </td>
 </tr>
 <tr style='height:21.55pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:.05in .1in .05in .1in;height:21.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Full Thickness wounds</span></p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:21.55pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>31.9 ± 10.1<br>
  (7)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:21.55pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>36.3 ± 26.0<br>
  (14)</span></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Mixed wounds</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>(deep partial and full thickness) </span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>40.2 ± 17.1<br>
  (44)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>27.7 ± 15.8<br>
  (59)</span></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Non-autografted mixed wounds</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>29.5 ± 12.1<br>
  (11)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>30.3 ± 15.5<br>
  (22)</span></p>
  </td>
 </tr>
 <tr style='height:26.25pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;padding:.05in .1in .05in .1in;height:26.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Autografted mixed wounds</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:26.25pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>43.7 ± 17.3<br>
  (33)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:26.25pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>26.2 ± 16.0<br>
  (37)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*</span>These
comparisons should be interpreted with caution since they are based on groups </p>

<p class=MsoNormal style='line-height:normal'>that are not fully randomized.</p>

<p class=MsoNormal style='line-height:normal'><sup>1 </sup>ITT (Intent To Treat
population): all randomized patients</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The difference
in time to complete wound closure is mainly related to the wound care strategy
applied by the physician, where an attempt to minimise grafting and allow for
spontaneous epithelialisation of the wound areas that still have dermis may
prolong time to first autograft (time to autograft: NexoBrid: 14.7 days vs.
SOC: 5.9 days<i>)</i> and hence prolong complete wound closure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Efficacy data
generated in this study from a subgroup analysis for children and adolescents
are summarised below. The available data are limited and NexoBrid should not be
used in patients younger than 18 years. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>NexoBrid</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>SOC</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>p-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=574 colspan=4 valign=top style='width:430.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial-thickness wounds requiring excision/dermabrasion (surgery)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>23</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>22</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wounds requiring surgery</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>21.7%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>68.2%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0017</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area excised or dermabraded<sup>1</sup>
  (mean ± SD) </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7.3% ± 15.7%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>64.9% ± 46.4%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=574 colspan=4 valign=top style='width:430.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial-thickness wounds autografted</span></b><span lang=EN-GB>*</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>23</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>22</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  % of wounds
  autografted</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>21.7%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>31.8%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.4447</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area autografted (mean ± SD)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.1% ± 14.7%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>24.5% ± 40.6%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0754</span></p>
  </td>
 </tr>
 <tr>
  <td width=574 colspan=4 valign=top style='width:430.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial- and/or full-thickness wounds requiring excision/dermabrasion
  (surgery)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>29</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>41</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wounds requiring surgery</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>20.7%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>78%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area excised or dermabraded<sup>1</sup>
  (mean ± SD) </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7.9% ± 17.6%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-7.05pt;
  margin-bottom:0in;margin-left:-3.65pt;margin-bottom:.0001pt;text-align:center;
  line-height:normal'><span lang=EN-GB>73.3% ± 41.1%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=574 colspan=4 valign=top style='width:430.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Time to
  complete wound closure (time from ICF**)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  patients<sup>2</sup></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>14</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>15</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  Days to closure of last wound (mean ± SD)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>29.9 ± 14.3</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>32.1 ± 18.9</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.6075</span></p>
  </td>
 </tr>
 <tr>
  <td width=574 colspan=4 valign=top style='width:430.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Time to
  successful eschar removal</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  Number of patients</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>14</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>15</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Days (mean ±
  SD) from   injury</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>1.9 ± 0.8</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8.1 ± 6.3</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Days (mean ±
  SD) from   consent</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>0.9 ± 0.7</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.5 ± 5.9</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients not
  reported to have successful eschar removal </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>0</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>1</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>1</span></sup><span
lang=EN-GB> Measured at first session, if there was more than one surgery
session. <br>
<sup>2</sup> All randomised patients for whom data for complete wound closure
were available. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*The endpoint
can only be evaluated for deep partial-thickness wounds without full-thickness
areas because full-thickness burns always require grafting.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>** Informed Consent Form</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The European Medicines Agency has deferred the obligation to submit
the results of studies with NexoBrid in one or more subsets of the paediatric
population in the treatment of burns of external body surface (see section 4.2
for information on paediatric use).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB> </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Absorption </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The extent of
systemic absorption from a burn wound, C<sub>max</sub>, T<sub>max</sub>, AUC,
and t<sub>½</sub> of bromelain from NexoBrid have been investigated in 16 burn
patients with partial-thickness (mid- and deep-dermal) thermal burns. Average
TBSA was 10%. 60% of the treated wounds area was partial thickness and/or full
thickness. NexoBrid was applied once to the burn wound at a dose of 2&nbsp;g
NexoBrid Powder/20&nbsp;g gel/100&nbsp;cm<sup>2</sup> of skin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid serum
concentrations were determined using a modified sandwich
electrochemiluminescence (ECL) immunoassay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The range of total
dose applied was 5 to 30&nbsp;g concentrate of proteolytic enzymes enriched in
bromelain from NexoBrid. In 4 patients, having received a dose of 5, 9, 12 and
17&nbsp;g, respectively, there were indications of markedly higher systemic
absorption.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>C<sub>max</sub>
was 6020&nbsp;±&nbsp;5020&nbsp;ng/ml (mean&nbsp;±&nbsp;SD) for the group of 15
patients, with a range of 888 to 15,700&nbsp;ng/ml. In the 4 patients with
indications of higher absorption, dose-normalised C<sub>max</sub> ranged from 788&#8209;900&nbsp;ng/ml
per gram of NexoBrid. In the other patients, dose-normalised C<sub>max</sub> ranged
from 141&#8209;523&nbsp;ng/ml per gram of NexoBrid.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A C<sub>max</sub>
of 40µg/ml may be possible in humans administered NexoBrid under licensed
conditions, when it is considered that PK has only been evaluated in patients
with largely superficial burns, receiving half the maximum dose.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>The
AUC from time zero to 48&nbsp;hours after administration (AUC<sub>last</sub>)
was 43,400&nbsp;±&nbsp;46,100 ngh/ml (mean&nbsp;±&nbsp;SD) for the group of 15
patients, with a range of 4560&#8209;167,000&nbsp;ngh/ml. In the patients with
indications of higher absorption, dose-normalised (per gram of NexoBrid) AUC<sub>last</sub>
ranged from 4500&#8209;9820&nbsp;ngh/ml per gram of NexoBrid. In the other patients,
dose-normalised AUC<sub>last</sub> ranged from 887&#8209;3930&nbsp;ngh/ml per
gram of NexoBrid.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>These
results for C<sub>max</sub> and AUC<sub>last</sub> indicate that systemic
absorption may depend both on the applied NexoBrid dose (proportional to the
covered wound area) and other, patient-specific factors.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>T<sub>max</sub>
for 10 of the 15 patients was 2&nbsp;hours and in 5 patients T<sub>max</sub>
was 4&nbsp;hours.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Distribution
</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>According to a
literature report, in plasma, approximately 50% of bromelain binds to the human
plasma antiproteinases &#945;<sub>2</sub>-macroglobulin and &#945;<sub>1</sub>-antichymotrypsin.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Elimination:
</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Terminal
half-life (determined using data from 16 to 48&nbsp;hours post-dose for 12
patients) was 11.7&nbsp;±&nbsp;3.5&nbsp;hours (mean ± SD), with a range from 8.5
to 19.9&nbsp;hours.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacokinetic
parameters and the extent of absorption have not been studied in children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;line-height:normal'><span
lang=EN-GB>NexoBrid was well tolerated when applied to intact mini-pig skin but
caused severe irritation and pain when applied to damaged (abraded) skin.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><span
lang=EN-GB>A single intravenous infusion of a solution prepared from NexoBrid
powder in the mini-pig was well tolerated at dose levels of up to 12&nbsp;mg/kg
<i>(achieving plasma levels 2.5fold of the human plasma level after application
of the clinical proposed dosage to 15% TBSA)</i> but higher doses were overtly
toxic, causing haemorrhage in several tissues. Repeated intravenous injections
of doses up to 12&nbsp;mg/kg every third day in the mini-pig were well
tolerated for the first three injections but severe clinical signs of toxicity (e.g.
haemorrhages in several organs) were observed following the remaining three
injections. Such effects could still be seen after the recovery period of 2
weeks.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><span
lang=EN-GB>In embryo-foetal development studies in rats and rabbits,
intravenously administered NexoBrid revealed no evidence of indirect and direct
toxicity to the developing embryo/foetus. </span><span lang=EN-GB>However,
maternal exposure levels were considerably lower than those maximally reported
in clinical setting (10500 times lower than human AUC, 350 times lower than
the human C<sub>max</sub>). </span><span lang=EN-GB>Since NexoBrid was poorly
tolerated by the parent animals, these studies are not considered relevant for
human risk assessment. NexoBrid showed no genotoxic activity when investigated
in the standard set of <i>in vitro</i> and <i>in vivo</i> studies.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>NexoBrid
powder</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ammonium
sulphate </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Acetic acid </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span style='position:absolute;
z-index:251657216;margin-left:410px;margin-top:3px;width:120px;height:12px'><img
width=120 height=12 src="NexoBrid_files/image002.gif" alt="DGD (N=49)"></span><u>Gel</u></p>

<p class=MsoNormal style='line-height:normal'>Carbomer 980</p>

<p class=MsoNormal style='line-height:normal'>disodium phosphate anhydrous</p>

<p class=MsoNormal style='line-height:normal'>Sodium hydroxide </p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Water for
injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Topically applied medicinal products (such as silver sulfadiazine or
povidone-iodine) at the wound site must be removed and the wound cleansed prior
to NexoBrid application. Remaining antibacterial medicinal products may
interfere with the activity of NexoBrid by decreasing its efficacy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product must not be mixed with other medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>From a
microbiological point of view and as the enzymatic activity of the product
decreases progressively following mixing, the reconstituted product should be
used immediately after preparation (within 15&nbsp;minutes).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and
transport refrigerated (2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C&#8209;8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Store upright to keep the gel at the bottom of the bottle and in the
original package to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>6.5<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;g powder in
a vial (glass type II) sealed with a rubber (bromobutyl), stopper and covered
with a cap (aluminium), and 20&nbsp;g gel in a bottle (borosilicate, glass type
I), sealed with a rubber stopper and covered with a<span style='color:#1F497D'>
</span>screw cap (tamper-proof polypropylene).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Pack size of 1 vial of powder and 1 bottle of gel.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6     Special precautions for
disposal and other handling</span></b></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are
reports of occupational exposure to bromelain leading to sensitisation.
Sensitisation may have occurred due to inhalation of bromelain powder. Allergic
reactions to bromelain </span><span lang=EN-GB>include anaphylactic reactions
and other immediate-type reactions with manifestations such as bronchospasm,
angiooedema, urticaria, and mucosal and gastrointestinal reactions. This should
be considered when mixing NexoBrid powder with the gel. The powder should not
be inhaled.. See also section 4.4. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Accidental eye
exposure must be avoided. In case of eye exposure, exposed eyes must be
irrigated with copious amounts of water for at least 15&nbsp;minutes. In case
of skin exposure, NexoBrid must be rinsed off with water.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>NexoBrid gel
preparation (mixing powder with gel)</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The NexoBrid powder and gel are sterile. An aseptic
technique must be used when mixing the powder with the gel.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The powder vial must be opened by carefully
tearing off the aluminium cap and removing the rubber stopper.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>When opening the gel bottle, it must be
confirmed that the tamper-evident ring is separating from the bottles cap. If
the tamper-evident ring was already separated from the cap before opening, the
gel bottle must be discarded and another, new gel bottle used.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The powder is then transferred into the
corresponding gel bottle. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Powder and gel must be mixed thoroughly until a
uniform, slightly tan to slightly brown mixture is obtained. This usually
requires mixing the powder and the gel for 1 to 2&nbsp;minutes.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The gel should be prepared at the patients
bedside.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>MediWound Germany GmbH</p>

<p class=MsoNormal style='line-height:normal'>Eisenstrasse 5</p>

<p class=MsoNormal style='line-height:normal'>65428 Rüsselsheim</p>

<p class=MsoNormal style='line-height:normal'>Germany</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/803/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 18.12.2012</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal: 10.11.2017</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product </span><span
lang=EN-GB>is available on the website of the European Medicines Agency
http://www.ema.europa.eu.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
width=21 height=18 id="Picture 2" src="NexoBrid_files/image001.gif"
alt="BT_1000x858px"></span><span lang=EN-GB> This medicinal product is subject
to additional monitoring. This will allow quick identification of new safety
information. Healthcare professionals are asked to report any suspected adverse
reactions. See section 4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid
5&nbsp;g powder and gel for gel</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>2.       QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial
contains 5&nbsp;g of concentrate of proteolytic enzymes enriched in bromelain,
corresponding to 0.09&nbsp;g/g concentrate of proteolytic enzymes enriched in
bromelain after mixing (or 5&nbsp;g/55&nbsp;g gel).</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'>&nbsp;</p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'>The proteolytic enzymes are a mixture of enzymes from the
stem of <i>Ananas comosus</i> (pineapple plant).</p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=EMEAEnBodyText style='margin:0in;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText style='margin:0in;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and gel
for gel.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The powder is off-white to light tan. The gel is clear and
colourless.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.       Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid is
indicated for removal of eschar in adults with deep partial- and full-thickness
thermal burns<i>.</i></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.2<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid should
only be applied by trained healthcare professionals in specialist burn centres.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span
 lang=EN-GB>5&nbsp;g</span><span lang=EN-GB> NexoBrid powder in 50&nbsp;g gel
is applied to a burn wound area of 250&nbsp;cm<sup>2</sup>. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid should
not be applied to more than 15%&nbsp;Total Body Surface Area (TBSA) (see also
section 4.4,<i> </i>Coagulopathy).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid should
be left in contact with the burn for a duration of 4&nbsp;hours. There is very
limited information on the use of NexoBrid on areas where eschar remained after
the first application.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A second and
subsequent application is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
information on the use of NexoBrid in patients with renal impairment. These
patients should be carefully monitored.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
information on the use of NexoBrid in patients with hepatic impairment. These
patients should be carefully monitored.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly
patients</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Experience with
NexoBrid in elderly patients (&gt;65&nbsp;years) is limited. Benefit/risk
assessment should include consideration of the greater frequency of concomitant
disease or other medicinal product therapy in the elderly. No dose adjustment
is required.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of NexoBrid in children and adolescents younger than 18&nbsp;years
have not yet been established. Currently available data are described in section
4.8 and 5.1 but no recommendation on a posology can be made.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid is not
indicated for use in patients younger than 18&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Before use, the
powder must be mixed with the gel producing a uniform gel.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>NexoBrid should be applied to a clean, keratin-free
(blisters removed), and moist wound area.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Topically
applied medicinal products (such as silver sulfadiazine or povidone-iodine) at
the wound site must be removed and the wound must be cleansed prior to NexoBrid
application.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>See section 6.6
for instructions on NexoBrid gel preparation.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Preparation
of patient and wound area</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A total wound
area of not more than 15%&nbsp;TBSA can be treated with NexoBrid (see also
section 4.4,<i> </i>Coagulopathy).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain management must be used as commonly
practiced for an extensive dressing change; it should be initiated at least
15&nbsp;minutes prior to NexoBrid application.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must be cleaned thoroughly and the
superficial keratin layer or blisters removed from the wound area, as the
keratin will isolate the eschar from direct contact with NexoBrid and prevent
eschar removal by NexoBrid.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dressing soaked with an antibacterial solution
must be applied for 2&nbsp;hours.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>All topically applied antibacterial medicinal
products must be removed before applying NexoBrid. Remaining antibacterial
medicinal products may interfere with the activity of NexoBrid by decreasing
its efficacy.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The area from which you wish to remove the
eschar must be surrounded with a sterile paraffin ointment adhesive barrier by
applying it a few centimetres outside of the treatment area (using a
dispenser). The paraffin layer must not come into contact with the area to be
treated to avoid covering the eschar, thus isolating the eschar from direct
contact with NexoBrid.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>To prevent possible irritation of abraded skin by inadvertent
contact with NexoBrid</span><span lang=EN-GB> </span><span lang=EN-GB>and
possible bleeding from the wound bed, acute wound areas such as lacerations or
escharotomy incisions should be protected by a layer of a sterile fatty
ointment or fatty dressing (e.g. petrolatum gauze).</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Sterile isotonic sodium chloride 9&nbsp;mg/ml
(0.9%) solution must be sprinkled on the burn wound. The wound must be kept
moist during the application procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>NexoBrid
application</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Within 15&nbsp;minutes of mixing, NexoBrid must
be applied topically to the moistened burn wound, at a thickness of 1.5 to
3&nbsp;millimetres.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must then be covered with a sterile
occlusive film dressing that adheres to the sterile adhesive barrier material
applied as per the instruction above (see <i>Preparation of patient and wound
area</i>). The NexoBrid gel must fill the entire occlusive dressing, and
special care should be taken not to leave air under this occlusive dressing.
Gentle pressing of the occlusive dressing at the area of contact with the
adhesive barrier will ensure adherence between the occlusive film and the
sterile adhesive barrier and achieve complete containment of NexoBrid on the
treatment area.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dressed wound must be covered with a loose,
thick fluffy dressing, held in place with a bandage.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dressing must remain in place for
4&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Removal of
NexoBrid</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Appropriate preventive analgesia medicinal
products must be administered.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>After 4&nbsp;hours of NexoBrid treatment, the
occlusive dressing must be removed using aseptic techniques.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The adhesive barrier must be removed using a
sterile blunt-edged instrument (e.g., tongue depressor).</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dissolved eschar must be removed from the
wound by wiping it away with a sterile blunt-edged instrument.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must be wiped thoroughly first with a
large sterile dry gauze or napkin, followed by a sterile gauze or napkin that
has been soaked with sterile isotonic sodium chloride 9 mg/ml (0.9%) solution.
The treated area must be rubbed until the appearance of a pinkish surface with
bleeding points or a whitish tissue. Rubbing will not remove adhering
undissolved eschar in areas where the eschar still remains.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A dressing soaked with an antibacterial solution
must be applied for an additional 2&nbsp;hours.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Wound care
after debridement</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The debrided area must be covered immediately by
temporary or permanent skin substitutes or dressings to prevent desiccation
and/or formation of pseudoeschar and/or infection.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Before a permanent skin cover or temporary skin
substitute is applied to a freshly enzymatically debrided area, a soaking
wet-to-dry dressing must be applied. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Before application of the grafts or primary
dressing, the debrided bed must be cleaned and refreshed by, e.g., brushing or
scraping to allow dressing adherence.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Wounds with areas of full-thickness and deep
burn should be autografted as soon as possible after NexoBrid debridement.
Careful consideration should also be given to placing permanent skin covers
(e.g. autografts) on deep partial thickness wounds soon after NexoBrid
debridement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>          See
section 4.4.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each NexoBrid
vial, gel, or reconstituted gel should be used for a single patient only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;text-align:justify;line-height:
normal'><span lang=EN-GB>Hypersensitivity to the active substance, to
pineapples or papain (see also section 4.4), or to any of the excipients listed
in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concentrate of
proteolytic enzymes enriched in bromelain is systemically absorbed from burn
wound areas (see section 5.2).</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>NexoBrid is not recommended for use on:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:1.3pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>penetrating burn wounds where foreign materials
(e.g. implants, pacemakers, and shunts) and<span style='color:black'>/ or vital
structures (e.g. larger vessels, eyes) are or could become exposed during
debridement</span>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:1.3pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>chemical burn wounds.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:1.3pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>wounds contaminated with
radioactive and other hazardous substances to avoid unforeseeable reactions
with the product and an increased risk of spreading the noxious substance.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Use in patients with cardiopulmonary and pulmonary disease</span></u></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><span
lang=EN-GB>NexoBrid should be used with caution in patients with<u> </u>cardiopulmonary
and pulmonary disease, including pulmonary burn trauma and suspected pulmonary
burn trauma.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><span
lang=EN-GB>General principles of proper burn wound care must be adhered to when
using NexoBrid. This includes proper wound cover for the exposed tissue.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Burns for which there is limited or no experience</span></u></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
experience of the use of NexoBrid on:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:1.3pt;margin-bottom:0in;
margin-left:28.1pt;margin-bottom:.0001pt;text-indent:-28.1pt;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>perineal and genital burns.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:1.3pt;margin-bottom:0in;
margin-left:28.1pt;margin-bottom:.0001pt;text-indent:-28.1pt;line-height:normal'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>electrical burns.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is limited
information on the use of NexoBrid on facial burn wounds.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;line-height:normal'><span
lang=EN-GB>NexoBrid must be used with caution in such patients. Eyes should be
carefully protected during treatment of facial burns using adhesive barrier
petroleum ointment.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><span
lang=EN-GB>There is limited pharmacokinetic data in patients with TBSA of more
than 15%. Due to safety considerations (see also section 4.4,<i> </i>Coagulopathy)
NexoBrid should not be applied to more than 15%Total Body Surface Area (TBSA).</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Prevention of wound complications</span></u></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In NexoBrid
studies wounds with visible dermal remnants were allowed to heal by spontaneous
epithelialisation. In several cases adequate healing did not occur and
autografting was required at a later date, leading to significant delays in
wound closure which is associated with increased risk of wound-related
complications. Therefore, wounds with areas of full-thickness and deep burn
should be autografted as soon as possible after NexoBrid debridement (see
section 5.1 for study results). Careful consideration should also be given to
placing permanent skin covers (e.g. autografts) on deep partial thickness
wounds soon after NexoBrid debridement. See also section 4.2 and 4.8.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;line-height:normal'><span
lang=EN-GB>As in the case of surgically debrided bed, in order to prevent
desiccation and/or formation of pseudoeschar and/or infection, the debrided
area should be covered immediately by temporary or permanent skin substitutes
or dressings. When applying a permanent skin cover (e.g., autograft) or
temporary skin substitute (e.g., allograft) to a freshly enzymatically debrided
area, care should be taken to clean and refresh the debrided bed by, e.g.,
brushing or scraping to allow dressing adherence.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Eye protection</span></u></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>Direct contact with the eyes should be avoided. If there is a risk
of eye contact, the patients eyes should be protected with fatty ophthalmic
ointment.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>In case of eye exposure, irrigate exposed eyes with copious amounts
of water for at least 15&nbsp;minutes. </span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Hypersensitivity reactions, skin exposure</span></u></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-align:justify;line-height:
normal'><span lang=EN-GB>There have been reports of serious allergic reactions
including anaphylaxis (with manifestations such as rash, erythema, hypotension,
tachycardia) in patients undergoing debridement with NexoBrid.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-align:justify;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Allergic reactions to bromelain have been reported in
the literature (including anaphylactic reactions and other immediate-type
reactions with manifestations such as bronchospasm, angiooedema, urticaria, and
mucosal and gastrointestinal reactions)</span>. <span lang=EN-GB>In addition, a
delayed-type allergic skin reaction (cheilitis) after longer-term dermal
exposure (mouthwash) as well as suspected sensitisation following oral exposure
and following repeated occupational airway exposure have been reported.. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>The potential of NexoBrid (a protein product) to cause
sensitisation should be taken into account when re-exposing patients to
bromelain-containing products at a later point in time. The use of NexoBrid in subsequent
burn injury is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>In case of skin exposure, NexoBrid should be rinsed off
with water to reduce the likelihood of skin sensitisation (see section 6.6).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Cross-sensitivity</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Cross-sensitivity between bromelain and papain as well
as latex proteins (known as latex-fruit syndrome), bee venom, and olive tree
pollen has been reported in the literature.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Coagulopathy</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>It is not known if NexoBrid application has any clinically relevant
effect on haemostasis.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>An increase in heart rate (including tachycardia), reduction of
platelet aggregation and plasma fibrinogen levels and a moderate increase in
partial thromboplastin and prothrombin times have been reported in the
literature as possible effects following oral administration of bromelain. <i>In
vitro</i> and animal data suggest that bromelain can also promote fibrinolysis.
During the clinical development of NexoBrid, there was no indication of an
increased bleeding tendency or bleeding at the site of debridement. </span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>NexoBrid should be used with caution in patients with disorders of
coagulation, low platelet counts and increased risk of bleeding from other
causes e.g. peptic ulcers and sepsis.</span></p>

<p class=Listenabsatz1 style='margin-left:0in;text-align:justify;line-height:
normal'><span lang=EN-GB>Patients should be monitored for possible signs of
coagulation abnormalities.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Monitoring</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In addition to routine monitoring for burn patients (e.g., vital
signs, volume/water/electrolyte status, complete blood count, serum albumin and
hepatic enzyme levels), patients treated with NexoBrid should be monitored for:</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rise in body temperature. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Signs of local and systemic inflammatory and
infectious processes. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Conditions that could be precipitated or
worsened by analgesic premedication (e.g., gastric dilatation, nausea and risk
of sudden vomiting, constipation) or antibiotic prophylaxis (e.g., diarrhoea). </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Signs of local or systemic allergic reactions.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Potential effects on haemostasis (see above).</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;line-height:normal'><i><s><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></i></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Removal of topically applied antibacterial medicinal products before
NexoBrid application</span></u></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><span
lang=EN-GB>All topically applied antibacterial medicinal products must be
removed before applying NexoBrid. Remaining antibacterial medicinal products
may interfere with the activity of NexoBrid by decreasing its efficacy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5     Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies with NexoBrid have been performed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reduction of platelet aggregation and plasma fibrinogen levels and a
moderate increase in partial thromboplastin and prothrombin times have been
reported as possible effects following oral administration of bromelain. </span><i><span
lang=EN-GB>In vitro</span></i><span lang=EN-GB> and animal data suggest that
bromelain can also promote fibrinolysis. Caution and monitoring is therefore
needed when prescribing concomitant medicinal products that affect coagulation.
See also section 4.4.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>NexoBrid, when absorbed, is an inhibitor of cytochrome P 450 2C8
(CYP2C8) and P450 2C9 (CYP2C9). This should be taken into account if NexoBrid
is used in patients receiving CYP2C8 substrates (including amiodarone,
amodiaquine, chloroquine, fluvastatin, paclitaxel, pioglitazone, repaglinide,
rosiglitazone, sorafenib and torasemide) and CYP2C9 substrates (including </span><span
lang=EN-GB>ibuprofen, tolbutamide, glipizide, losartan, celecoxib, warfarin,
and phenytoin). </span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Topically applied antibacterial medicinal products (e.g. silver
sulfadiazine or povidone iodine) may decrease the efficacy of NexoBrid (see
section 4.4).</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Bromelain
may enhance the actions of fluorouracil and vincristine. Patients should be
monitored for increased toxicity</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Bromelain
may enhance the hypotensive effect of ACE inhibitors, causing larger decreases
in blood pressure than expected. Blood pressure should be monitored in patients
receiving ACE inhibitors Bromelain may increase drowsiness caused by some
medicinal products (e.g., benzodiazepines, barbiturates, narcotics and
antidepressants). This should be taken into account when dosing such products</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6     </span></b><b><span lang=EN-GB>Fertility, p</span></b><b><span
lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in'><span lang=EN-GB>There
are no data from the use of NexoBrid in pregnant women.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Animal studies are insufficient to properly assess the potential of
NexoBrid to interfere with embryonal/foetal development (see section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Since the safe
use of NexoBrid during pregnancy has not yet been established, NexoBrid is not
recommended during pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is unknown
whether concentrate of proteolytic enzymes enriched in bromelain or its
metabolites are excreted in human milk. A risk to newborns/infants cannot be
excluded. Breast-feeding should be discontinued at least 4&nbsp;days from NexoBrid
application initiation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No studies were
performed to assess the effects of NexoBrid on fertility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7     Effects on ability to drive and use
machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not relevant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.8<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><u><span
lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The most commonly reported adverse reactions of the use of NexoBrid
are local pain and transient pyrexia/hyperthermia. When NexoBrid was used in a
regimen which included recommended preventive analgesia as routinely practiced
for extensive dressing changes in burn patients as well as antibacterial
soaking of the treatment area before and after NexoBrid application (see
section 4.2), pain was reported in 3.6% of patients, pyrexia/hyperthermia in
19.1% of patients. The frequency of pain and pyrexia/hyperthermia was higher
without these precautionary measures (see below).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The following definitions apply to the frequency terminology used
hereafter:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very common (&#8805;1/10)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Common (&#8805;1/100 to &lt;1/10)</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Uncommon (</span><span lang=EN-GB
style='font-family:Symbol'>³</span><span lang=EN-GB>1/1,000 to &lt;1/100)</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Rare (</span><span lang=EN-GB
style='font-family:Symbol'>³</span><span lang=EN-GB>1/10,000 to &lt;1/1,000)</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>Very rare (&lt;1/10,000)</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Not known (cannot be estimated from the available data)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The frequencies of the adverse reactions presented below reflect the
use of NexoBrid to remove eschar from deep partial- or full-thickness burns in
a regimen with local antibacterial prophylaxis, recommended analgesia, as well
as coverage of the wound area after application of NexoBrid for 4&nbsp;hours
with an occlusive dressing for containment of NexoBrid on the wound.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>An asterisk (*) indicates that additional information on the
respective adverse reaction is provided below the list of adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Infections and infestations</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Common:             Wound infection</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Common:             Wound complication*</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>General disorders and administration site conditions</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Very common:      Pyrexia/hyperthermia* </span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-85.05pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>Common:             Local pain* </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Immune system disorders</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Not known:          Serious allergic reactions including anaphylaxis
</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Pyrexia/hyperthermia</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In studies implementing routine antibacterial soaking of the
treatment area before and after NexoBrid application (see section 4.2)</span><span
lang=EN-GB> pyrexia or hyperthermia was reported in 19.1% of patients treated
with NexoBrid and in 15.8% of the control patients treated according standard
of care. In the NexoBrid group, the event was graded as mild, moderate or
severe in 9.1%, 9.1%, and 0% of patients, respectively.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In studies without antibacterial soaking, pyrexia or hyperthermia
was reported in 35.6% of NexoBrid-treated patients compared with 18.6% in
control patients. In the NexoBrid group, the event was graded as mild, moderate
or severe in 30.0%, 5.6% and 1.1% of patients, respectively.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Pain</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In studies where the NexoBrid regimen included recommended
preventive analgesia as routinely practiced for extensive dressing changes in
burn patients (see section 4.2) </span><span lang=EN-GB>local pain was reported
in 3.6% of patients treated with NexoBrid and in 4.0% of the control patients
treated according to standard of care. In the NexoBrid group, the event was
graded as mild, moderate or severe in 0.9%, 0.9%, and 1.8% of patients,
respectively.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In studies where analgesia was provided in NexoBrid-treated patients
on an on-demand basis, </span><span lang=EN-GB>local pain was reported in 23.3%
of patients treated with NexoBrid and in 11.4% of the control patients. In the
NexoBrid group, the event was graded as mild, moderate or severe in 6.7%, 7.8%
and 8.9% of patients, respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Wound
complications</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In phase 2 and phase 3 clinical studies,
certain types of wound complications were reported more frequently in the
NexoBrid group than in the group treated according to the study sites Standard
of Care (SOC)<span style='color:#00B050'>. </span>These events included: Wound
deepening or desiccation (decomposition) in 5 patients (2.4%) with NexoBrid and
0 with SOC as well as (partial) graft failure in 6 patients (2.9%) with
NexoBrid and 2 (1.6%) with SOC (see section 4.4).</span></p>

<p class=Listenabsatz1 style='margin-left:0in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>General Infections</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In phase 2 and phase 3 clinical studies general infections (not
wound related. e.g. urinary tract infections, viral infections) were reported
more frequently in the NexoBrid group (0.147 events per patient) than in the
group treated according to SOC (0.079 events per patient).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There is only limited safety data from the use in the paediatric
population. From these data it is expected that the overall safety profile in
children 4&nbsp;years of age and older and in adolescents is similar to the
profile in adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with </span>concentrate
of <span lang=EN-GB>proteolytic enzymes enriched in bromelain </span><span
lang=EN-GB>prepared in a powder:gel ratio of 1:5 (0.16g per g of mixed gel) in
patients with deep partial- and/or full-thickness burns within the framework of
a clinical study did not result in significantly different safety findings when
compared to treatment with concentrate of proteolytic enzymes enriched in
bromelain prepared in a powder:gel ratio of 1:10 (0.09 g per 1g of mixed gel).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Preparations for treatment of wounds and ulcers, proteolytic enzymes;
ATC code: D03BA03</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Concentrate of proteolytic enzymes </span>enriched in bromelain <span
lang=EN-GB>is a debriding agent, applied topically for removal of eschar in
deep partial- and full-thickness burns. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Mechanism of
action</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The mixture of
enzymes in NexoBrid dissolves burn wound eschar. The specific components
responsible for this effect have not been identified. The major constituent is
stem bromelain.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Clinical
efficacy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During clinical
development, a total of 362 patients were treated with the concentrate of
proteolytic enzymes enriched in bromelain. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy of
NexoBrid in humans was evaluated, compared to standard of care, in a
randomised, multi-centre, multi-national, open-label, confirmatory phase 3
study in hospitalised patients with deep partial- and/or full-thickness thermal
burns of 5 to 30% Total Body Surface Area (TBSA), but with total burn wounds of
no more than 30% TBSA.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid
(2&nbsp;g/100&nbsp;cm<sup>2</sup>, corresponding to 0.02&nbsp;g/cm<sup>2</sup>)
was used as described in section 4.2.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Standard of care
consisted of primary surgical excision and/or nonsurgical debridement using
topical medicinal products to induce maceration and autolysis of eschar
according to each study sites standard practice.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The age range in
the group treated with NexoBrid was 4.4 to 55.7&nbsp;years. The age range in
the SOC group was 5.1 to 55.7&nbsp;years. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy of
eschar removal was evaluated by determining the percentage of wound area left
with eschar that required further removal by excision or dermabrasion, and the
percentage of wounds requiring such surgical removal. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effect on
the timing of eschar removal was evaluated in patients with successful eschar
removal (with at least 90% eschar removal in all wounds of a patient combined),
by determining the time from injury as well as from informed consent to
successful removal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The co-primary
endpoints for the efficacy analysis were:</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the percentage of deep partial thickness wounds
requiring excision or dermabrasion, and</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the percentage of deep partial thickness wounds
autografted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This endpoint
can only be evaluated for deep partial-thickness wounds without full-thickness
areas because full-thickness burns always require grafting.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Efficacy data
generated in this study for all age groups combined as well as from a subgroup
analysis for children and adolescents are summarised below. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>NexoBrid</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.05pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>SOC</span></b></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>p-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=555 colspan=4 valign=top style='width:416.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial-thickness wounds requiring excision/dermabrasion (surgery)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>106</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>88</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wounds requiring surgery</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>15.1%</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>62.5%</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area excised or dermabraded<sup>1</sup>
  (mean ± SD) </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>5.5% ± 14.6</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>52.0% ± 44.5</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=555 colspan=4 valign=top style='width:416.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial-thickness wounds autografted</span></b><span lang=EN-GB>*</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>106</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>88</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  % of wounds
  autografted</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>17.9%</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>34.1%</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0099</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area autografted (mean ± SD)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8.4% ± 21.3</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.5pt;text-align:center;
  line-height:normal'><span lang=EN-GB>21.5% ± 34.8</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0054</span></p>
  </td>
 </tr>
 <tr>
  <td width=555 colspan=4 valign=top style='width:416.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial- and/or full-thickness wounds requiring excision/dermabrasion
  (surgery)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>163</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.05pt;text-align:center;
  line-height:normal'><span lang=EN-GB>170</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wounds requiring surgery</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>24.5%</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.05pt;text-align:center;
  line-height:normal'><span lang=EN-GB>70.0%</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area excised or dermabraded<sup>1</sup>
  (mean ± SD) </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>13.1% ± 26.9</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-2.05pt;text-align:center;
  line-height:normal'><span lang=EN-GB>56.7% ± 43.3</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=555 colspan=4 valign=top style='width:416.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Time to
  complete wound closure (time from ICF**)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  patients<sup>2</sup></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>70</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>78</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  Days to closure of last wound (mean ± SD)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>36.2 ± 18.5</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>28.8 ± 15.6</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0185</span></p>
  </td>
 </tr>
 <tr>
  <td width=555 colspan=4 valign=top style='width:416.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Time to
  successful eschar removal</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  Number of patients</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>67</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>73</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Days (mean ±
  SD) from   injury</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>2.2 ± 1.4</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8.7 ± 5.7</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Days (mean ±
  SD) from   consent</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>0.8 ± 0.8</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.7 ± 5.8</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients not
  reported to have successful eschar removal </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.2pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.6pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>1</span></sup><span
lang=EN-GB> Measured at first session, if there was more than one surgery
session. <br>
<sup>2</sup> All randomised patients for whom data for complete wound closure
were available. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*The endpoint
can only be evaluated for deep partial-thickness wounds without full-thickness
areas because full-thickness burns always require grafting.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>** Informed
Consent Form</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table shows results in mixed wounds.</span> The comparisons in mixed wounds
should be interpreted with caution since they are based on groups that are not
fully randomized and the mixed wounds treated by NexoBrid were overall larger
and had a larger full thickness area.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Mixed wounds
(with partial and full-thickness area) requiring excision/dermabrasion
(surgery)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>NexoBrid</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(Number of
  wounds)</span></b></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>SOC</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(Number of
  wounds)</span></b></p>
  </td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>% of wounds
  requiring surgery</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>41.7% (20/48)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>78.3% (47/60)</span></p>
  </td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>% of wound
  area excised or dermabraded</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>25.5% (n=48)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>64.0% (n=60)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Mixed wounds
(with partial and full-thickness area) autografted</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>NexoBrid</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(Number of
  wounds)</span></b></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>SOC</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(Number of
  wounds)</span></b></p>
  </td>
 </tr>
 <tr style='height:21.9pt'>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.9pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>All mixed
  burns baseline characteristics</span></b></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>48 wounds</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:21.9pt'>
  <p class=MsoNormal style='line-height:normal'>60 wounds</p>
  </td>
 </tr>
 <tr style='height:13.2pt'>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Size</span></b><span
  lang=EN-GB>: % mean TBSA </span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>7.43</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.2pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6.33</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Depth</span></b><span
  lang=EN-GB>: </span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Superficial
  (%TBSA)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.67</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.92</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  DPT (% TBSA)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3.85</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3.13</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  FT    (%
  TBSA)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.90</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.29</span></p>
  </td>
 </tr>
 <tr style='height:16.15pt'>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Incidence of
  autograft</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>70.8% (34/48)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>63.3% (38/60) </span></p>
  </td>
 </tr>
 <tr style='height:13.65pt'>
  <td width=197 valign=top style='width:2.05in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.65pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>% wound area
  autografted </span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.65pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>55.5% (n=48)</span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.65pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>45.8% (n=60) </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table shows the time to complete wound closure from start of debridement.*</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=532
 style='border-collapse:collapse'>
 <tr style='height:17.5pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>Wound Type </span></b></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border:solid black 1.0pt;
  border-left:none;padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB style='color:black'>NexoBrid </span></b></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border:solid black 1.0pt;
  border-left:none;padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB style='color:black'>SOC </span></b></p>
  </td>
 </tr>
 <tr style='height:17.5pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB style='color:black'>Days (mean ± SD)<br>
  (Number of wounds) </span></b></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB style='color:black'>Days (mean ± SD)<br>
  (Number of wounds)</span></b></p>
  </td>
 </tr>
 <tr style='height:19.75pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>All wounds (ITT<sup>1</sup>)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>30.5 ± 16.9<br>
  (154)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>26.1 ± 16.0 <br>
  (164) </span></p>
  </td>
 </tr>
 <tr style='height:19.75pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Non-autografted wounds (ITT)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>23.9 ± 13.0<br>
  (95)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>24.5 ± 14.1<br>
  (85)</span></p>
  </td>
 </tr>
 <tr style='height:19.75pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Autografted wounds (ITT)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>41.0 ± 17.3<br>
  (59)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:19.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>27.8 ± 17.7<br>
  (79)</span></p>
  </td>
 </tr>
 <tr style='height:18.15pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:.05in .1in .05in .1in;height:18.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Deep Partial Thickness wounds</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:18.15pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>26.6 ± 15.4<br>
  (101)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:18.15pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>23.7 ± 13.6<br>
  (87)</span></p>
  </td>
 </tr>
 <tr style='height:21.55pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:.05in .1in .05in .1in;height:21.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Full Thickness wounds</span></p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:21.55pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>31.9 ± 10.1<br>
  (7)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:.05in .1in .05in .1in;height:21.55pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>36.3 ± 26.0<br>
  (14)</span></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Mixed wounds</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>(deep partial and full thickness) </span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>40.2 ± 17.1<br>
  (44)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>27.7 ± 15.8<br>
  (59)</span></p>
  </td>
 </tr>
 <tr style='height:17.0pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Non-autografted mixed wounds</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>29.5 ± 12.1<br>
  (11)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:17.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>30.3 ± 15.5<br>
  (22)</span></p>
  </td>
 </tr>
 <tr style='height:26.25pt'>
  <td width=232 valign=top style='width:173.7pt;border:solid black 1.0pt;
  border-top:none;padding:.05in .1in .05in .1in;height:26.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Autografted mixed wounds</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:26.25pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>43.7 ± 17.3<br>
  (33)</span></p>
  </td>
  <td width=150 valign=top style='width:112.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in .1in .05in .1in;height:26.25pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>26.2 ± 16.0<br>
  (37)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*</span>These
comparisons should be interpreted with caution since they are based on groups </p>

<p class=MsoNormal style='line-height:normal'>that are not fully randomized.</p>

<p class=MsoNormal style='line-height:normal'><sup>1 </sup>ITT (Intent To Treat
population): all randomized patients</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The difference
in time to complete wound closure is mainly related to the wound care strategy
applied by the physician, where an attempt to minimise grafting and allow for
spontaneous epithelialisation of the wound areas that still have dermis may
prolong time to first autograft (time to autograft: NexoBrid: 14.7 days vs.
SOC: 5.9 days<i>)</i> and hence prolong complete wound closure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Efficacy data
generated in this study from a subgroup analysis for children and adolescents
are summarised below. The available data are limited and NexoBrid should not be
used in patients younger than 18 years. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>NexoBrid</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>SOC</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>p-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=574 colspan=4 valign=top style='width:430.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial-thickness wounds requiring excision/dermabrasion (surgery)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>23</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>22</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wounds requiring surgery</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>21.7%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>68.2%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0017</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area excised or dermabraded<sup>1</sup>
  (mean ± SD) </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7.3% ± 15.7%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>64.9% ± 46.4%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=574 colspan=4 valign=top style='width:430.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial-thickness wounds autografted</span></b><span lang=EN-GB>*</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>23</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>22</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  % of wounds
  autografted</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>21.7%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>31.8%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.4447</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area autografted (mean ± SD)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.1% ± 14.7%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>24.5% ± 40.6%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0754</span></p>
  </td>
 </tr>
 <tr>
  <td width=574 colspan=4 valign=top style='width:430.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deep
  partial- and/or full-thickness wounds requiring excision/dermabrasion
  (surgery)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  wounds</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>29</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>41</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wounds requiring surgery</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>20.7%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>78%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  % of wound area excised or dermabraded<sup>1</sup>
  (mean ± SD) </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7.9% ± 17.6%</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-7.05pt;
  margin-bottom:0in;margin-left:-3.65pt;margin-bottom:.0001pt;text-align:center;
  line-height:normal'><span lang=EN-GB>73.3% ± 41.1%</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=574 colspan=4 valign=top style='width:430.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Time to
  complete wound closure (time from ICF**)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Number of
  patients<sup>2</sup></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>14</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>15</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  Days to closure of last wound (mean ± SD)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>29.9 ± 14.3</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>32.1 ± 18.9</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.6075</span></p>
  </td>
 </tr>
 <tr>
  <td width=574 colspan=4 valign=top style='width:430.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Time to
  successful eschar removal</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
  normal'><span lang=EN-GB>  Number of patients</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>14</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>15</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Days (mean ±
  SD) from   injury</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>1.9 ± 0.8</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8.1 ± 6.3</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  Days (mean ±
  SD) from   consent</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>0.9 ± 0.7</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.5 ± 5.9</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients not
  reported to have successful eschar removal </span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-1.85pt;text-align:center;
  line-height:normal'><span lang=EN-GB>0</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:-3.65pt;text-align:center;
  line-height:normal'><span lang=EN-GB>1</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>1</span></sup><span
lang=EN-GB> Measured at first session, if there was more than one surgery
session. <br>
<sup>2</sup> All randomised patients for whom data for complete wound closure
were available. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*The endpoint
can only be evaluated for deep partial-thickness wounds without full-thickness
areas because full-thickness burns always require grafting.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>** Informed Consent Form</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The European Medicines Agency has deferred the obligation to submit
the results of studies with NexoBrid in one or more subsets of the paediatric
population in the treatment of burns of external body surface (see section 4.2
for information on paediatric use).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Absorption</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The extent of
systemic absorption from a burn wound, C<sub>max</sub>, T<sub>max</sub>, AUC,
and t<sub>½</sub> of bromelain from NexoBrid have been investigated in 16 burn
patients with partial-thickness (mid- and deep-dermal) thermal burns. Average
TBSA was 10%. 60% of the treated wounds area was partial thickness and/or full
thickness. NexoBrid was applied once to the burn wound at a dose of 2&nbsp;g
NexoBrid Powder/20&nbsp;g gel/100&nbsp;cm<sup>2</sup> of skin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid serum
concentrations were determined using a modified sandwich
electrochemiluminescence (ECL) immunoassay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The range of
total dose applied was 5 to 30&nbsp;g concentrate of proteolytic enzymes
enriched in bromelain from NexoBrid. In 4 patients, having received a dose of
5, 9, 12 and 17&nbsp;g, respectively, there were indications of markedly higher
systemic absorption.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>C<sub>max</sub>
was 6020&nbsp;±&nbsp;5020&nbsp;ng/ml (mean&nbsp;±&nbsp;SD) for the group of 15
patients, with a range of 888 to 15,700&nbsp;ng/ml. In the 4 patients with
indications of higher absorption, dose-normalised C<sub>max</sub> ranged from
788&#8209;900&nbsp;ng/ml per gram of NexoBrid. In the other patients, dose-normalised
C<sub>max</sub> ranged from 141&#8209;523&nbsp;ng/ml per gram of NexoBrid.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A C<sub>max</sub>
of 40µg/ml may be possible in humans administered NexoBrid under licensed
conditions, when it is considered that PK has only been evaluated in patients
with largely superficial burns, receiving half the maximum dose.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>The
AUC from time zero to 48&nbsp;hours after administration (AUC<sub>last</sub>)
was 43,400&nbsp;±&nbsp;46,100 ngh/ml (mean&nbsp;±&nbsp;SD) for the group of 15
patients, with a range of 4560&#8209;167,000&nbsp;ngh/ml. In the patients with
indications of higher absorption, dose-normalised (per gram of NexoBrid) AUC<sub>last</sub>
ranged from 4500&#8209;9820&nbsp;ngh/ml per gram of NexoBrid. In the other
patients, dose-normalised AUC<sub>last</sub> ranged from 887&#8209;3930&nbsp;ngh/ml
per gram of NexoBrid.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>These
results for C<sub>max</sub> and AUC<sub>last</sub> indicate that systemic
absorption may depend both on the applied NexoBrid dose (proportional to the
covered wound area) and other, patient-specific factors.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>T<sub>max</sub>
for 10 of the 15 patients was 2&nbsp;hours and in 5 patients T<sub>max</sub>
was 4&nbsp;hours.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Distribution</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>According
to a literature report, in plasma, approximately 50% of bromelain binds to the
human plasma antiproteinases &#945;<sub>2</sub>-macroglobulin and &#945;<sub>1</sub>-antichymotrypsin.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Elimination</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Terminal
half-life (determined using data from 16 to 48&nbsp;hours post-dose for 12 patients)
was 11.7&nbsp;±&nbsp;3.5&nbsp;hours (mean ± SD), with a range from 8.5 to
19.9&nbsp;hours.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacokinetic
parameters and the extent of absorption have not been studied in children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;line-height:normal'><span
lang=EN-GB>NexoBrid was well tolerated when applied to intact mini-pig skin but
caused severe irritation and pain when applied to damaged (abraded) skin.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;line-height:normal'><span
lang=EN-GB>A single intravenous infusion of a solution prepared from NexoBrid
powder in the mini-pig was well tolerated at dose levels of up to 12&nbsp;mg/kg
<i>(achieving plasma levels 2.5fold of the human plasma level after application
of the clinical proposed dosage to 15% TBSA)</i> but higher doses were overtly
toxic, causing haemorrhage in several tissues. Repeated intravenous injections
of doses up to 12&nbsp;mg/kg every third day in the mini-pig were well
tolerated for the first three injections but severe clinical signs of toxicity
(e.g. haemorrhages in several organs) were observed following the remaining
three injections. Such effects could still be seen after the recovery period of
2 weeks.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal'><span
lang=EN-GB>In embryo-foetal development studies in rats and rabbits,
intravenously administered NexoBrid revealed no evidence of indirect and direct
toxicity to the developing embryo/foetus. </span><span lang=EN-GB>However,
maternal exposure levels were considerably lower than those maximally reported
in clinical setting (10500 times lower than human AUC, 350 times lower than
the human C<sub>max</sub>). </span><span lang=EN-GB>Since NexoBrid was poorly
tolerated by the parent animals, these studies are not considered relevant for
human risk assessment. NexoBrid showed no genotoxic activity when investigated
in the standard set of <i>in vitro</i> and <i>in vivo</i> studies.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>NexoBrid
powder</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ammonium
sulphate </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Acetic acid </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span style='position:absolute;
z-index:251658240;margin-left:410px;margin-top:3px;width:120px;height:12px'><img
width=120 height=12 src="NexoBrid_files/image002.gif" alt="DGD (N=49)"></span><u>Gel</u></p>

<p class=MsoNormal style='line-height:normal'>Carbomer 980</p>

<p class=MsoNormal style='line-height:normal'>disodium phosphate anhydrous</p>

<p class=MsoNormal style='line-height:normal'>Sodium hydroxide </p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Water for
injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Topically applied medicinal products (such as silver sulfadiazine or
povidone-iodine) at the wound site must be removed and the wound cleansed prior
to NexoBrid application. Remaining antibacterial medicinal products may
interfere with the activity of NexoBrid by decreasing its efficacy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product must not be mixed with other medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>From a
microbiological point of view and as the enzymatic activity of the product
decreases progressively following mixing, the reconstituted product should be
used immediately after preparation (within 15&nbsp;minutes).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and
transport refrigerated (2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C&#8209;8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Store upright to keep the gel at the bottom of the bottle and in the
original package to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5&nbsp;g powder
in a vial (glass type II) sealed with a rubber (bromobutyl), stopper and
covered with a cap (aluminium), and 50&nbsp;g gel in a bottle (borosilicate,
glass type I), sealed with a </span><span lang=EN-GB>rubber stopper and covered
with a<span style='color:#1F497D'> </span></span><span lang=EN-GB>screw cap
(tamper-proof polypropylene).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Pack size of 1 vial of powder and 1 bottle of gel.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.6     Special precautions for disposal and other
handling</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are
reports of occupational exposure to bromelain leading to sensitisation.
Sensitisation may have occurred due to inhalation of bromelain powder. Allergic
reactions to bromelain </span><span lang=EN-GB>include anaphylactic reactions
and other immediate-type reactions with manifestations such as bronchospasm,
angiooedema, urticaria, and mucosal and gastrointestinal reactions. This should
be considered when mixing NexoBrid powder with the gel. The powder should not
be inhaled. See also section 4.4. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Accidental eye
exposure must be avoided. In case of eye exposure, exposed eyes must be
irrigated with copious amounts of water for at least 15&nbsp;minutes. In case
of skin exposure, NexoBrid must be rinsed off with water.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>NexoBrid gel
preparation (mixing powder with gel)</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The NexoBrid powder and gel are sterile. An
aseptic technique must be used when mixing the powder with the gel.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The powder vial must be opened by carefully
tearing off the aluminium cap and removing the rubber stopper.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>When opening the gel bottle, it must be
confirmed that the tamper-evident ring is separating from the bottles cap. If
the tamper-evident ring was already separated from the cap before opening, the
gel bottle must be discarded and another, new gel bottle used.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The powder is then transferred into the
corresponding gel bottle. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Powder and gel must be mixed thoroughly until a
uniform, slightly tan to slightly brown mixture is obtained. This usually
requires mixing the powder and the gel for 1 to 2&nbsp;minutes.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The gel should be prepared at the patients
bedside.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>MediWound Germany GmbH</p>

<p class=MsoNormal style='line-height:normal'>Eisenstrasse 5</p>

<p class=MsoNormal style='line-height:normal'>65428 Rüsselsheim</p>

<p class=MsoNormal style='line-height:normal'>Germany</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/803/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 18.12.2012</span></p>

<p class=MsoNormal style='line-height:normal'>Date of latest renewal:
10.11.2017</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product </span><span
lang=EN-GB>is available on the website of the European Medicines Agency
http://www.ema.europa.eu.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=NormalAgency><b><u><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=NormalAgency><b><u><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=NormalAgency><b><u><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=NormalAgency><b><u><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=NormalAgency><b><u><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=NormalAgency><b><u><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center'><span
lang=EN-GB style='font-family:"Times New Roman",serif;text-transform:uppercase'>Annex
II</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=No-numheading3Agency style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>A.        <span style='text-transform:
uppercase'>Manufacturers of the biological active substance and manufacturer responsible
for batch release</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase;font-weight:normal'> </span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=No-numheading3Agency style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif;text-transform:uppercase'>B.      Conditions
or restrictions regarding supply and use</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=No-numheading3Agency style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif;text-transform:uppercase'>C.      Other
conditions and requirements of the marketing      authorisation</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'>A.      </span></b><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>MANUFACTURERS OF
THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Name
and address of the manufacturers of the biological active substance</span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>MediWound Ltd.</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>42 Hayarkon St. </span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>81227 Yavne</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Israel</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Name
and address of the manufacturer responsible for batch release</span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hälsa
Pharma GmbH</span></p>

<p class=NormalAgency><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hafenweg
18-20</span></p>

<p class=NormalAgency><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>D-48155
Münster</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Germany</span></p>

<p class=NormalAgency><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></b></p>

<p class=NormalAgency><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;text-transform:uppercase'>B.      Conditions or
restrictions regarding supply and use</span></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Medicinal product subject to restricted medical
prescription (see Annex I: Summary of Product Characteristics, section 4.2).</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;text-transform:uppercase'>C.      Other conditions and
requirements of the Marketing      Authorisation </span></b></p>

<p class=NormalAgency><b><i><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></i></b></p>

<p class=NormalAgency><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Pharmacovigilance system</span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The MAH
must ensure that the system of pharmacovigilance presented in Module 1.8.1. of
the Marketing Authorisation is in place and functioning before and whilst the
medicinal product is on the market.</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Risk Management Plan (RMP)</span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The MAH
shall perform the pharmacovigilance activities detailed in the
Pharmacovigilance Plan, as agreed in the Risk Management Plan presented in
Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the
RMP agreed by the Committee for Medicinal Products for Human Use (CHMP).</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>As per
the CHMP Guideline on Risk Management Systems for medicinal products for human
use, the updated RMP should be submitted at the same time as the next Periodic
Safety Update Report (PSUR).</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>In addition, an updated RMP should be submitted</span></p>

<p class=NormalAgency style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol;color:#003399'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>When
new information is received that may impact on the current Safety
Specification, Pharmacovigilance Plan or risk minimisation activities</span></p>

<p class=NormalAgency style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol;color:#003399'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Within
60 days of an important (pharmacovigilance or risk minimisation) milestone
being reached</span></p>

<p class=NormalAgency style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol;color:#003399'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>At
the request of the European Medicines Agency.</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>PSURs</span></u></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
layout-grid-mode:line'>The PSUR cycle for the medicinal product should follow
the standard requirements until otherwise agreed by the CHMP. </span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:19.85pt;text-indent:-19.85pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'>Conditions or restrictions with regard to the safe
and effective use of the medicinal product</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Prior to launch in each Member State, the </span><span
lang=EN-GB>Marketing Authorisation Holder </span><span lang=EN-GB>MAH shall
agree the content and format of the educational programme with the national
competent authority. </span><span lang=EN-GB>The Marketing Authorisation Holder
(MAH) should ensure that, at launch, all Healthcare Professionals in specialist
burn centres who are expected to use and/or prescribe NexoBrid &nbsp;receive a
specific training and are provided with an Educational pack.&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The MAH should&nbsp;undertake a controlled
distribution of NexoBrid to ensure that the product is not available&nbsp;for
use&nbsp;at a centre until at least one surgeon at the centre has received
formal training in the use of&nbsp; NexoBrid.&nbsp; This is in addition to the
educational material which all potential users should receive.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt'><span lang=EN-GB>The educational
pack should contain the following:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:0in;text-indent:0in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Summary of Product Characteristics and Patient
Information Leaflet </span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Healthcare Professional information pack</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The Healthcare Professional information
pack should be a step by step treatment guide that includes information on the
following key elements:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt'><span lang=EN-GB>Before
prescribing NexoBrid</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:49.35pt;text-indent:-22.4pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The limitation of the &nbsp;total area than can
be treated to 15% TBSA </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:49.5pt;text-indent:-22.5pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The risk of allergic reaction and of cross
reactivity and &nbsp;the contraindication in patients allergic to
&nbsp;pineapple and papain or to previous application of the product</span></p>

<p class=MsoNormal style='margin-left:49.5pt;text-indent:-22.5pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The risk of increased mortality in patients with
cardiopulmonary diseases</span></p>

<p class=MsoNormal style='margin-left:27.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:17.85pt;text-indent:-17.85pt'><span lang=EN-GB>Before applying
NexoBrid</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:49.5pt;text-indent:-22.4pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The need for &nbsp;</span><span lang=EN-GB>pain
management </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:49.5pt;text-indent:-22.4pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The need for wound cleansing and preparation
before treatment with </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:85.5pt;text-indent:-22.4pt;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Application of a dressing soaked with an
antibacterial solution for two hours before NexoBrid application</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:85.5pt;text-indent:-22.4pt;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Protection of surrounding skin areas </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:49.5pt;text-indent:-22.4pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The method of preparation of NexoBrid and of its
application to wound area</span></p>

<p class=MsoNormal style='margin-left:27.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:17.85pt;text-indent:-17.85pt'><span lang=EN-GB>After applying
NexoBrid </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:49.5pt;text-indent:-22.5pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The removal of NexoBrid and of dissolved eschar</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:49.5pt;text-indent:-22.5pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound assessment and the warning against any
repeat treatment</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:49.5pt;text-indent:-22.5pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound management after NexoBrid treatment
with</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:1.25in;text-indent:-27.0pt;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Application of a dressing soaked with an
antibacterial solution for two hours </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:1.25in;text-indent:-27.0pt;line-height:normal'><span lang=EN-GB
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Performance of grafting procedures as soon as
possible after debridement</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:49.5pt;text-indent:-22.5pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The fact that NexoBrid may cause an allergic
reaction, an increased tendency to bleed and severe local irritation and that &nbsp;patients
should be monitored for signs or symptoms of these</span></p>

<p class=NormalAgency style='margin-left:49.5pt;text-indent:-22.5pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>   The
fact that patients should be monitored for signs and symptoms of wound and
systemic infections</span></p>

<p class=NormalAgency style='margin-left:27.0pt'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:19.85pt;text-indent:-19.85pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol;text-transform:uppercase'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'>Obligation to conduct post-authorisation measures</span></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;layout-grid-mode:line'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
layout-grid-mode:line'>The MAH shall complete, within the stated timeframe, the
following measures:</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
layout-grid-mode:line'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=519 valign=top style='width:389.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BodytextAgency><b><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;layout-grid-mode:line'>Description</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BodytextAgency><b><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;layout-grid-mode:line'>Due date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=519 valign=top style='width:389.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>The MAH
  shall conducts a study on enzymatic debridement in burns patients (children
  and adults): A comparison to standard of care (protocol MW2010-03-02), based
  on a CHMP approved protocol.</span></p>
  </td>
  <td width=123 valign=top style='width:92.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>31/12/2020</span></p>
  </td>
 </tr>
</table>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>A. LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>OUTER CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid 2&nbsp;g
powder and gel for gel</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Concentrate of <span lang=EN-GB>proteolytic
enzymes </span>enriched in bromelain</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>One vial contains 2&nbsp;g of concentrate
of proteolytic enzymes enriched in bromelain, corresponding to 0.09&nbsp;g/g
concentrate of proteolytic enzymes enriched in bromelain after mixing (or
2&nbsp;g/22&nbsp;g gel).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>Excipients for the powder: Acetic acid, ammonium sulphate.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>Excipients for the gel: </span>Carbomer 980, disodium phosphate
anhydrous, sodium hydroxide, <span lang=EN-GB>water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Powder and gel for gel</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 vial of 2&nbsp;g
powder</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 bottle of 20&nbsp;g
of gel</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and gel
to be mixed before application.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and transport
refrigerated (2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C&#8209;8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=Listenabsatz1 style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Store in the original package in order to protect from light. Store
upright.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'>MediWound Germany GmbH</p>

<p class=MsoNormal style='line-height:normal'>65428 Rüsselsheim</p>

<p class=MsoNormal style='line-height:normal'>Germany</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/803/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='background:lightgrey'>&lt;2D barcode carrying the unique
identifier included.&gt;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:#008100'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&lt; PC: {number} </span></p>

<p class=MsoNormal><span lang=EN-GB>SN: {number} </span></p>

<p class=MsoNormal><span lang=EN-GB>NN: {number} &gt;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>OUTER CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid
5&nbsp;g powder and gel for gel</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Concentrate of <span lang=EN-GB>proteolytic
enzymes </span>enriched in bromelain</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>One vial contains 5&nbsp;g of concentrate
of proteolytic enzymes enriched in bromelain, corresponding to 0.09&nbsp;g/g
concentrate of proteolytic enzymes enriched in bromelain after mixing (or
5&nbsp;g/55&nbsp;g gel).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>Excipients for the powder: Acetic acid, ammonium sulphate.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>Excipients for the gel: </span>Carbomer 980, disodium phosphate
anhydrous, sodium hydroxide, <span lang=EN-GB>water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Powder and gel for gel</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 vial of
5&nbsp;g powder</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 bottle of
50&nbsp;g of gel</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and gel
to be mixed before application.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and
transport refrigerated (2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C&#8209;8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=Listenabsatz1 style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Store in the original package in order to protect from light. Store
upright.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'>MediWound Germany GmbH</p>

<p class=MsoNormal style='line-height:normal'>65428 Rüsselsheim</p>

<p class=MsoNormal style='line-height:normal'>Germany</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/803/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='background:lightgrey'>&lt;2D barcode carrying the unique
identifier included.&gt;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:#008100'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&lt; PC: {number} </span></p>

<p class=MsoNormal><span lang=EN-GB>SN: {number} </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NN: {number}
&gt;<span style='color:black;background:#CCCCCC'><br clear=all
style='page-break-before:always'>
</span></span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>NexoBrid powder </span></b><b><span
lang=EN-GB>(vial)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid
2&nbsp;g powder</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Concentrate of <span lang=EN-GB>proteolytic
enzymes </span>enriched in bromelain</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>One vial contains 2&nbsp;g of concentrate
of proteolytic enzymes enriched in bromelain, corresponding to 0.09&nbsp;g/g
concentrate of proteolytic enzymes enriched in bromelain after mixing (or
2&nbsp;g/22&nbsp;g gel).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
Acetic acid, ammonium sulphate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Powder</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;g</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and gel
to be mixed before application.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cutaneous use.</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and
transport refrigerated (2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C&#8209;8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C).</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSEDMEDICINAL PRODUCTS
OR WASTE MATERIALS DEREIvED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>MediWound Germany GmbH</p>

<p class=MsoNormal style='line-height:normal'>65428 Rüsselsheim</p>

<p class=MsoNormal style='line-height:normal'>Germany</p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/803/001 </span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS FOR USE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&lt;Not applicable.&gt;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:#008100'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&lt;Not applicable.&gt;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>NexoBrid powder </span></b><b><span
lang=EN-GB>(vial)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid
5&nbsp;g powder </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Concentrate of <span lang=EN-GB>proteolytic
enzymes </span>enriched in bromelain</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>One vial contains 5&nbsp;g of concentrate
of proteolytic enzymes enriched in bromelain, corresponding to 0.09&nbsp;g/g
concentrate of proteolytic enzymes enriched in bromelain after mixing (or
5&nbsp;g/55&nbsp;g gel).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
Acetic acid, ammonium sulphate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Powder</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5&nbsp;g </span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and gel
to be mixed before application.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cutaneous use.</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and
transport refrigerated (2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C&#8209;8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C).</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSEDMEDICINAL PRODUCTS
OR WASTE MATERIALS DEREIvED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>MediWound Germany GmbH</p>

<p class=MsoNormal style='line-height:normal'>65428 Rüsselsheim</p>

<p class=MsoNormal style='line-height:normal'>Germany</p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/803/002 </span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS FOR USE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&lt;Not applicable.&gt;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:#008100'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&lt;Not applicable.&gt;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>Gel for NexoBrid powder</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gel for NexoBrid
2&nbsp;g</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concentrate of proteolytic enzymes enriched
in bromelain: 0.09&nbsp;g/g (or 2&nbsp;g/22&nbsp;g gel) after mixing.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>Excipients: </span>Carbomer 980, disodium phosphate anhydrous,
sodium hydroxide, <span lang=EN-GB>water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gel</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;g</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and gel
to be mixed before application.</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and
transport refrigerated (2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C&#8209;8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=Listenabsatz1 style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Store in the original package in order to protect from light. Store
upright.</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>MediWound Germany GmbH</p>

<p class=MsoNormal style='line-height:normal'>65428 Rüsselsheim</p>

<p class=MsoNormal style='line-height:normal'>Germany</p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>EU/1/12/803/001</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS FOR USE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&lt;Not applicable.&gt;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:#008100'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&lt;Not applicable.&gt;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>Gel for NexoBrid powder</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gel for NexoBrid
5&nbsp;g</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concentrate of proteolytic enzymes enriched
in bromelain: 0.09&nbsp;g/g (or 5&nbsp;g/55&nbsp;g gel) after mixing.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span
lang=EN-GB>Excipients: </span>Carbomer 980, disodium phosphate anhydrous,
sodium hydroxide, <span lang=EN-GB>water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gel</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>50&nbsp;g</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and gel
to be mixed before application.</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For single use
only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and
transport refrigerated (2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C&#8209;8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=Listenabsatz1 style='margin-left:0in;line-height:normal'><span
lang=EN-GB>Store in the original package in order to protect from light. Store
upright.</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>MediWound Germany GmbH</p>

<p class=MsoNormal style='line-height:normal'>65428 Rüsselsheim</p>

<p class=MsoNormal style='line-height:normal'>Germany</p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/803/002 </span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS FOR USE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&lt;Not applicable.&gt;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='color:#008100'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&lt;Not applicable.&gt;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>B. PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>NexoBrid 2&nbsp;g powder and gel for gel</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>Concentrate
of <span lang=EN-GB>proteolytic enzymes </span>enriched in bromelain</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
width=21 height=18 id="Picture 3" src="NexoBrid_files/image003.gif"
alt="BT_1000x858px"></span><span lang=EN-GB> This medicine is subject to
additional monitoring. This will allow quick identification of new safety
information. You can help by reporting any side effects you may get. See the
end of section 4 for how to report side effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor. This includes any possible side effects not listed in this leaflet.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>1.      What NexoBrid is and what it is used for</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>2.      What you need to know before NexoBrid is used</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>3.      How NexoBrid is used</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>4.      Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>How NexoBrid is stored</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>6.      Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What </span></b><b><span lang=EN-GB>NexoBrid
is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What NexoBrid is</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid
contains a mixture of enzymes called </span>concentrate of <span lang=EN-GB>proteolytic
enzymes </span>enriched in bromelain,<span lang=EN-GB> which is produced from
an extract from the stem of the pineapple plant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What NexoBrid
is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>NexoBrid is used in adult patients to remove burnt tissue from deep
or partially deep burn wounds of the skin. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Using </span>NexoBrid may reduce the need for, or the extent of,
surgical removal of burnt tissue and/or skin transplantation.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before</span></b><b><span
lang=EN-GB> NexoBrid is used</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>NexoBrid must
not be used:</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-        if you are allergic to bromelain</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-        if you are allergic to pineapples</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>-        if
you are allergic to papain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        if you are allergic to any of the other
ingredients of the powder or gel (listed in section 6).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Talk to your
doctor or nurse before NexoBrid is used if</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>-        you have a heart disease;<br>
-        you have a lung disease;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>-        your lung has been, or may have been damaged by inhalation
of smoke; </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-        </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-        you are allergic to
latex, bee stings, or olive tree pollen. If so, you may also experience
allergic reactions to NexoBrid;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-        .</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Allergic reactions can cause, for example, breathing difficulties,
swelling of the skin, hives, other skin reactions, redness of the skin, low blood
pressure, fast heart rate<span style='color:black'> </span>and abdominal
discomfort, or a combination of such effects. If you notice any of these signs
or symptoms, inform your doctor or caregiver immediately.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Allergic reactions can be severe and require medical treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In case of skin contact, rinse NexoBrid off with water. This is to
make it less likely that you develop an allergic reaction to NexoBrid.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>The use of
NexoBrid to remove burnt tissue may lead to fever, to wound inflammation or
wound infection, and possibly to general infection. You may be checked
regularly for these conditions. You may receive medicines to prevent or treat
infections.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>NexoBrid may reduce the ability of your blood to form clots, which
increases the risk of bleeding. </span>NexoBrid should be used with caution if
you have a general tendency to bleed, a stomach ulcer, blood poisoning, or
another condition that could cause you to bleed. <span lang=EN-GB>After
treatment with NexoBrid your doctor may check your blood coagulation levels.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>Direct contact of NexoBrid with the eyes should be avoided. If
NexoBrid goes into the eyes, wash them with lots of water for at least
15&nbsp;minutes.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>To prevent wound-healing problems, the treated burn wound will be
covered as soon as possible by temporary or permanent skin substitutes or
dressings.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>NexoBrid should not be used in
chemical burn wounds, contaminated wounds and wounds where NexoBrid could come
in contact with foreign materials (for example, implants, pacemakers, and
shunts) or large blood vessels, the eyes or other important body parts.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><b><span lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>NexoBrid is
not for use in patients younger than 18&nbsp;years.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and NexoBrid</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Tell your doctor if you are taking, have recently taken or might
take any other medicines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Your doctor will
be cautious and watch for signs of reduced blood coagulation or bleeding when
prescribing other medicines that affect blood coagulation, because NexoBrid may
reduce blood coagulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>NexoBrid may:</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB>-        increase the effects of certain medicines
that are inactivated by a liver enzyme called CYP2C8 and CYP2C9. This is
because NexoBrid can be absorbed from the burn wound into the blood stream . Examples
of such medicines are: </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - amiodarone (used to treat certain forms of irregular
heartbeat),</span></p>

<p class=Listenabsatz1CxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - amodiaquine and chloroquine (used to treat malaria and
some forms of inflammation),<br>
- fluvastatin (used to treat high cholesterol),<br>
- pioglitazone, rosiglitazone, repaglinide, </span><span lang=EN-GB>tolbutamide
and glipizide (used to treat diabetes), <br>
- paclitaxel and sorafenib (used to treat cancer), <br>
- torasemide (used to increase urine flow),</span></p>

<p class=Listenabsatz1CxSpMiddle style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - ibuprofen ( used to treat fever, pain and some forms of
inflammation), </span></p>

<p class=Listenabsatz1CxSpMiddle style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - losartan (used to treat high blood pressure), </span></p>

<p class=Listenabsatz1CxSpMiddle style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - celecoxib (used to treat some forms of inflammation), </span></p>

<p class=Listenabsatz1CxSpMiddle style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - warfarin (used to reduce blood coagulation), and</span></p>

<p class=Listenabsatz1CxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - phenytoin (used to treat epilepsy).</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-        intensify your reaction to the cancer medicines
fluorouracil and vincristine.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB>-        cause an unwanted drop in blood pressure
when you are treated with medicines called ACE inhibitors, which are used to
treat high blood pressure and other conditions. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB>-        increase drowsiness when used at the same
time with medicines that can cause drowsiness. These medicines include, for
example, sleep medications, so-called tranquilizers, some pain medications and
antidepressants.</span></p>

<p class=MsoListParagraphCxSpMiddle><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are not
sure whether you are taking any of the medicines mentioned above, ask your
doctor before NexoBrid is used.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of
NexoBrid during pregnancy is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As a
precautionary measure, you should not breast-feed for at least 4 days after
NexoBrid application.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are pregnant or breast-feeding, think you may be pregnant or
are planning to have a baby, talk to your doctor or pharmacist before this
medicine is used.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How </span></b><b><span lang=EN-GB>NexoBrid
is used</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>NexoBrid is
for use by specialists in burn clinics only.<span lang=EN-GB> It will be
prepared directly before use and applied by a doctor or another healthcare
professional.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
 lang=EN-GB>2&nbsp;g</span><span lang=EN-GB> NexoBrid powder mixed in 20&nbsp;g
gel is applied to a burn wound area of 100&nbsp;cm<sup>2</sup>.</span></p>

<p class=Default><span style='font-size:11.0pt'>It should be left for
4&nbsp;hours, and then be removed</span><span style='font-size:11.0pt;
color:windowtext'>. A second and subsequent application is not recommended. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>        NexoBrid should not be applied to more than
15% (one eighth) of the total body surface.</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Instructions for the preparation of the NexoBrid gel are given at
the end of this leaflet in the section intended for medical or healthcare
professionals.</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Before it is
applied to a burn wound, NexoBrid powder is mixed into a gel. It should be used
within 15&nbsp;minutes after mixing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>        NexoBrid will be applied to a wound area that
is clean, blister free, and moist.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>        Other medicines (such as silver sulfadiazine
or povidone-iodine) will be removed from the wound area before NexoBrid is
applied.</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>        Before NexoBrid application, a dressing
soaked with an antibacterial solution will be applied for 2&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>        You will be given appropriate medicine to
prevent and treat pain at least 15&nbsp;minutes before NexoBrid is applied. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>        After NexoBrid and the dead tissue have been
removed from the wound, a dressing soaked with an antibacterial solution will be
applied for an additional 2&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>        The vial containing NexoBrid powder, gel bottle,
and the prepared NexoBrid gel should only be used for one patient.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If too much NexoBrid is used </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If too much NexoBrid gel is applied on a burn wound, excess gel may
be wiped off.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Allergic reactions to NexoBrid can occur
and can cause, for example, breathing difficulties, swelling of the skin,
hives, redness of the skin, low blood pressure, fast heart rate and
sickness/vomiting/stomach cramp, or a combination of such effects. If you
notice any of these symptoms or signs, inform your doctor or caregiver
immediately.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Very common
side effects (may affect more than 1 in 10 people)</span></p>

<p class=CCDSMandatoryInformationbullet style='margin-left:28.1pt;text-indent:
-28.1pt;line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever</span></p>

<p class=CCDSMandatoryInformationbullet style='margin-left:0in;text-indent:
0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Common side
effects (may affect up to 1 in 10 people)</span></p>

<p class=CCDSMandatoryInformationbullet style='margin-left:28.1pt;text-indent:
-28.1pt;line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain (even if medicines are used to prevent or
lessen pain caused by the removal of burnt tissue)</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>-        Infection of the burn wound</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Complications of the wound including; wound
opening, wounds drying out and breaking down and failure of skin grafts to heal
properly</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you get any
side effects, talk to your doctor or nurse.</span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:red'> </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;background:lightgrey'>Appendix
V</span></a></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.       How </span></b><b><span lang=EN-GB>NexoBrid
is stored</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use
NexoBrid after the expiry date which is stated on the label of the vial,
bottle, and box after EXP. The expiry date refers to the last day of that
month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and
transport refrigerated (2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C&#8209;8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C).</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in'><span lang=EN-GB>NexoBrid
must be stored upright to keep the gel at the bottom of the bottle and in the
original package to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>NexoBrid should be used within 15&nbsp;minutes after mixing the
powder with the gel.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>NexoBrid contains </span></b></p>

<p class=CCDSMandatoryInformationbullet style='margin-left:28.1pt;text-indent:
-28.1pt;line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance (in the powder in the vial)
is a </span>concentrate of <span lang=EN-GB>proteolytic enzymes </span>enriched
in bromelain: 2&nbsp;g, corresponding to 0.09&nbsp;g/g concentrate of <span
lang=EN-GB>proteolytic enzymes </span>enriched in bromelain after mixing<span
lang=EN-GB>. The other ingredients are: for the powder: ammonium sulphate and
acetic acid and for the gel carbomer 980, disodium phosphate anhydrous, sodium
hydroxide, and water for injections.</span></p>

<p class=CCDSMandatoryInformationbullet style='margin-left:0in;text-indent:
0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>NexoBrid looks like and contents
of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>NexoBrid is provided as a powder and gel
for gel (powder in a vial (2&nbsp;g) and gel in a bottle (20&nbsp;g)), pack
size of 1 (a pack contains one vial of powder and one bottle of gel)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The powder is off-white to light tan and
the gel is clear and colourless.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>MediWound Germany
GmbH</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Eisenstrasse 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>65428 Rüsselsheim</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=DE>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=SV>Manufacturer</span><span
lang=SV>:</span></p>

<p class=NormalAgency><span lang=SV style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hälsa
Pharma GmbH</span></p>

<p class=NormalAgency><span lang=SV style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hafenweg
18-20</span></p>

<p class=NormalAgency><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>D-48155
Münster</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local representative
of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tél/Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal;layout-grid-mode:
  char'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Te&#1083;:
  +800 22232425</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>MediWound GmbH </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tél/Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:49.5pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>&#268;eská
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>MediWound GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt;
  height:49.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Magyarország</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>Tel.: +800 22232425</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tlf: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>Tel: +800 22232425</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tlf: +800
  22232425</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#932;&#951;&#955;:
  +2111990962</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Österreich</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>España</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>Tél: +800 22232425</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel.: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tél: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Portugal</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +15517564</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>România</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +40 0312295632</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'><br clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Ísland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Sími: +800
  22232425</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Slovenská
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>MediWound GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=SV style='color:green'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Puh/Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#932;&#951;&#955;:
  +800 22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><em><span
lang=EN-GB>&nbsp;</span></em></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in &lt;</span></b><span lang=EN-GB>{<b>MM/YYYY</b>}&gt;
&lt;</span><span lang=EN-GB>{<b>month YYYY</b>}<b>.</b>&gt;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: http://www.ema.europa.eu. There are also links to
other websites about rare diseases and treatments.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>---------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal'><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Preparation
and administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>From a
microbiological point of view and as the enzymatic activity of the product
decreases progressively following mixing, the reconstituted product should be
used immediately after preparation (within 15&nbsp;minutes).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>NexoBrid should be applied to a clean, keratin-free
(blisters removed), and moist wound area.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Topically
applied medicinal products (such as silver sulfadiazine or povidone-iodine) at
the wound site must be removed and the wound must be cleansed prior to NexoBrid
application.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Preparation
of patient and wound area</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A total wound area of not more than
15%&nbsp;TBSA can be treated by NexoBrid.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain management must be used as commonly
practiced for an extensive dressing change; it should be initiated at least
15&nbsp;minutes prior to NexoBrid application.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must be cleaned thoroughly and the
superficial keratin layer or blisters removed from the wound area, as the
keratin will isolate the eschar from direct contact with NexoBrid and prevent
eschar removal by NexoBrid.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dressing soaked with an antibacterial solution must
be applied for 2&nbsp;hours.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>All topically applied antibacterial medicinal
products must be removed before applying NexoBrid. Remaining antibacterial medicinal
products may interfere with the activity of NexoBrid by decreasing its
efficacy.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The area from which you wish to remove the
eschar must be surrounded with a sterile paraffin ointment adhesive barrier by
applying it a few centimetres outside of the treatment area (using a
dispenser). The paraffin layer must not come into contact with the area to be
treated in order to avoid covering the eschar, thus isolating the eschar from
direct contact with NexoBrid.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>To prevent possible irritation of abraded skin by inadvertent
contact with NexoBrid and possible bleeding from the wound bed, acute wound
areas such as lacerations or escharotomy incisions should be protected by a
layer of a sterile fatty ointment or fatty dressing (e.g. petrolatum gauze).</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Sterile isotonic sodium chloride 9&nbsp;mg/ml
(0.9%) solution must be sprinkled on the burn wound. The wound must be kept moist
during the application procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>NexoBrid gel
preparation (mixing powder with gel)</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The NexoBrid powder and gel are sterile. Aseptic
technique must be used when mixing NexoBrid powder with the gel. The powder
should not be inhaled.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The NexoBrid powder vial must be opened by
carefully tearing off the aluminium cap and removing the rubber stopper.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>When opening the gel bottle, it must be
confirmed that the tamper-evident ring is separating from the bottles cap. If
the tamper-evident ring was already separated from the cap before opening, the
gel bottle must be discarded and another, new gel bottle used.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>NexoBrid powder is then transferred into the
corresponding gel bottle. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>NexoBrid powder and gel must be mixed thoroughly
until a uniform, slightly tan to slightly brown mixture is obtained. This
usually requires mixing the NexoBrid powder and the gel for 1 to
2&nbsp;minutes.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>NexoBrid gel should be prepared at the patients
bedside.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>NexoBrid
application</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Within 15&nbsp;minutes of mixing, NexoBrid must be
applied topically to the burn wound, at a thickness of 1.5 to
3&nbsp;millimetres.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must then be covered with a sterile
occlusive film dressing that adheres to the sterile adhesive barrier material
applied as per the instruction above (see <i>Preparation of patient and wound
area</i>). The NexoBrid gel should fill the entire occlusive dressing, and
special care should be taken not to leave air under this occlusive dressing.
Gentle pressing of the occlusive dressing at the area of contact with the
adhesive barrier will ensure adherence between the occlusive film and the
barrier and achieve complete containment of NexoBrid on the treatment area.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dressed wound must be covered with a loose,
thick fluffy dressing, held in place with a bandage.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dressing must remain in place for
4&nbsp;hours.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Removal of
NexoBrid</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Appropriate preventive analgesia medicinal
products must be administered.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>After 4&nbsp;hours of NexoBrid treatment, the
occlusive dressing must be removed using aseptic techniques.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The adhesive barrier must be removed using a
sterile blunt-edged instrument (e.g., tongue depressor).</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dissolved eschar must be removed from the
wound by wiping it away with a sterile blunt-edged instrument.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must be wiped thoroughly first with a
large sterile dry gauze or napkin, followed by a sterile gauze or napkin that
has been soaked with sterile isotonic sodium chloride 9&nbsp;mg/ml (0.9%) solution.
The treated area must be rubbed until the appearance of a pinkish surface with
bleeding points or a whitish tissue. Rubbing will not remove adhering
undissolved eschar in areas where the eschar still remains.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A dressing soaked with an antibacterial solution
must be applied for an additional 2&nbsp;hours.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Wound care
after debridement</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The debrided area must be covered immediately by
temporary or permanent skin substitutes or dressings to prevent desiccation
and/or formation of pseudoeschar and/or infection.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Before a permanent skin cover or temporary skin
substitute is applied to a freshly enzymatically debrided area, a soaking
wet-to-dry dressing should be applied. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Before application of the grafts and primary
dressing, the debrided bed must be cleaned and refreshed by, e.g., brushing or
scraping to allow dressing adherence.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Wounds with areas of full thickness and deep burn
should be autografted as soon as possible after NexoBrid debridement. Careful
consideration should also be given to placing permanent skin covers (e.g.
autografts) on deep partial thickness wounds soon after NexoBrid debridement.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Recommendations
for safe handling</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each NexoBrid
vial, gel, or reconstituted gel should be used for a single patient only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are
reports of occupational exposure to bromelain leading to sensitisation.
Sensitisation may have occurred due to inhalation of bromelain powder. Allergic
reactions to bromelain </span><span lang=EN-GB>include anaphylactic reactions
and other immediate-type reactions with manifestations such as bronchospasm,
angiooedema, urticaria, and mucosal and gastrointestinal reactions. This should
be considered when mixing NexoBrid powder with the gel. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Avoid accidental
eye exposure. In case of eye exposure, irrigate exposed eyes with copious
amounts of water for at least 15&nbsp;minutes. In case of skin exposure, rinse
NexoBrid off with water.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Disposal</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>NexoBrid 5&nbsp;g powder and gel for gel</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>Concentrate
of <span lang=EN-GB>proteolytic enzymes </span>enriched in bromelain</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
width=21 height=18 id="Picture 4" src="NexoBrid_files/image003.gif"
alt="BT_1000x858px"></span><span lang=EN-GB> This medicine is subject to
additional monitoring. This will allow quick identification of new safety
information. You can help by reporting any side effects you may get. See the
end of section 4 for how to report side effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor. This includes any possible side effects not listed in this leaflet.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>1.      What NexoBrid is and what it is used for</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>2.      What you need to know before NexoBrid is used</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>3.      How NexoBrid is used</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>4.      Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>How NexoBrid is stored</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>6.      Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>1. What </span></b><b><span lang=EN-GB>NexoBrid is and what it is
used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What NexoBrid is</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NexoBrid
contains a mixture of enzymes called </span>concentrate of <span lang=EN-GB>proteolytic
enzymes </span>enriched in bromelain,<span lang=EN-GB> which is produced from
an extract from the stem of the pineapple plant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What NexoBrid
is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>NexoBrid is used in adult patients to remove burnt tissue from deep
or partially deep burn wounds of the skin. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Using </span>NexoBrid may reduce the need for, or the extent of,
surgical removal of burnt tissue and/or skin transplantation.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before</span></b><b><span
lang=EN-GB> NexoBrid is used</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>NexoBrid must
not be used:</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-        if you are allergic to bromelain</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB>-        if you are allergic to pineapples</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>-        if
you are allergic to papain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        if you are allergic to any of the other
ingredients of the powder or gel (listed in section 6).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Talk to your
doctor or nurse before NexoBrid is used if</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>-        you have a heart disease;<br>
-        you have a lung disease;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>-        your lung has been, or may have been damaged by inhalation
of smoke; </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-        </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-        you are allergic to
latex, bee stings, or olive tree pollen. If so, you may also experience
allergic reactions to NexoBrid;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-        </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Allergic reactions can cause, for example, breathing difficulties,
swelling of the skin, hives, other skin reactions, redness of the skin, low
blood pressure, fast heart rate<span style='color:black'> </span>and abdominal
discomfort, or a combination of such effects. If you notice any of these signs
or symptoms, inform your doctor or caregiver immediately.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Allergic reactions can be severe and require medical treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In case of skin contact, rinse NexoBrid off with water. This is to
make it less likely that you develop  an allergic reaction to NexoBrid.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>The use of
NexoBrid to remove burnt tissue may lead to fever, to wound inflammation or
wound infection, and possibly to general infection. You may be checked
regularly for these conditions. You may receive medicines to prevent or treat infections.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>NexoBrid may reduce the ability of your blood to form clots, which
increases the risk of bleeding. </span>NexoBrid should be used with caution if
you have a general tendency to bleed, a stomach ulcer, blood poisoning, or
another condition that could cause you to bleed. <span lang=EN-GB>After
treatment with NexoBrid your doctor may check your blood coagulation levels.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>Direct contact of NexoBrid with the eyes should be avoided. If
NexoBrid goes into the eyes, wash them with lots of water for at least
15&nbsp;minutes.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>To prevent wound-healing problems, the treated burn wound will be
covered as soon as possible by temporary or permanent skin substitutes or
dressings.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>NexoBrid should not be used in
chemical burn wounds, contaminated wounds and wounds where NexoBrid could come
in contact with foreign materials (for example, implants, pacemakers, and
shunts) or large blood vessels, the eyes or other important body parts.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><b><span lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>NexoBrid is
not for use in patients younger than 18&nbsp;years.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and NexoBrid</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Tell your doctor if you are taking, have recently taken or might
take any other medicines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Your doctor will
be cautious and watch for signs of reduced blood coagulation or bleeding when
prescribing other medicines that affect blood coagulation, because NexoBrid may
reduce blood coagulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>NexoBrid may:-<br>
increase the effects of certain medicines that are inactivated by a liver
enzyme called CYP2C8 and CYP2C9. This is because NexoBrid can be absorbed from
the burn wound into the blood stream. Examples of such medicines are: </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - amiodarone (used to treat certain forms of irregular
heartbeat),</span></p>

<p class=Listenabsatz1CxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - amodiaquine and chloroquine (used to treat malaria and
some forms of inflammation),<br>
- fluvastatin (used to treat high cholesterol),<br>
- pioglitazone, rosiglitazone, repaglinide, </span><span lang=EN-GB>tolbutamide
and glipizide (used to treat diabetes), <br>
- paclitaxel and sorafenib (used to treat cancer), <br>
- torasemide (used to increase urine flow),</span></p>

<p class=Listenabsatz1CxSpMiddle style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - ibuprofen ( used to treat fever, pain and some forms of
inflammation), </span></p>

<p class=Listenabsatz1CxSpMiddle style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - losartan (used to treat high blood pressure), </span></p>

<p class=Listenabsatz1CxSpMiddle style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - celecoxib (used to treat some forms of inflammation), </span></p>

<p class=Listenabsatz1CxSpMiddle style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - warfarin (used to reduce blood coagulation), and</span></p>

<p class=Listenabsatz1CxSpLast style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>          - phenytoin (used to treat epilepsy).</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-        intensify your reaction to the cancer medicines
fluorouracil and vincristine.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB>-        cause an unwanted drop in blood pressure
when you are treated with medicines called ACE inhibitors, which are used to
treat high blood pressure and other conditions. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span lang=EN-GB>-        increase drowsiness when used at the same
time with medicines that can cause drowsiness. These medicines include, for
example, sleep medications, so-called tranquilizers, some pain medications and
antidepressants.</span></p>

<p class=MsoListParagraphCxSpLast><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are not
sure whether you are taking any of the medicines mentioned above, ask your
doctor before NexoBrid is used.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of
NexoBrid during pregnancy is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As a
precautionary measure, you should not breast-feed for at least 4 days after
NexoBrid application.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are pregnant or breast-feeding, think you may be pregnant or
are planning to have a baby, talk to your doctor or pharmacist before this
medicine is used.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How </span></b><b><span lang=EN-GB>NexoBrid
is used</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>NexoBrid is
for use by specialists in burn clinics only.<span lang=EN-GB> It will be
prepared directly before use and applied by a doctor or another healthcare
professional.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>5&nbsp;g NexoBrid powder mixed in 50&nbsp;g
gel is applied to a burn wound area of 250&nbsp;cm<sup>2</sup>.</span></p>

<p class=Default><span style='font-size:11.0pt'>It should be left for
4&nbsp;hours, and then be removed</span><span style='font-size:11.0pt;
color:windowtext'>. A second and subsequent application is not recommended. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>        NexoBrid should not be applied to more than
15% (one eighth) of the total body surface.</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Instructions for the preparation of the NexoBrid gel are given at
the end of this leaflet in the section intended for medical or healthcare
professionals.</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Before it is
applied to a burn wound, NexoBrid powder is mixed into a gel. It should be used
within 15&nbsp;minutes after mixing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>        NexoBrid will be applied to a wound area that
is clean, blister free, and moist.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>        Other medicines (such as silver sulfadiazine
or povidone-iodine) will be removed from the wound area before NexoBrid is
applied.</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>        Before NexoBrid application, a dressing
soaked with an antibacterial solution will be applied for 2&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>        You will be given appropriate medicine to prevent
and treat pain at least 15&nbsp;minutes before NexoBrid is applied. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.2pt;text-indent:-28.2pt;line-height:
normal'><span lang=EN-GB>        After NexoBrid and the dead tissue have been
removed from the wound, a dressing soaked with an antibacterial solution will
be applied for an additional 2&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>        The vial containing NexoBrid powder, gel
bottle, and the prepared NexoBrid gel should only be used for one patient.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If too much NexoBrid is used </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If too much NexoBrid gel is applied on a burn wound, excess gel may
be wiped off.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Allergic reactions to NexoBrid can occur
and can cause, for example, breathing difficulties, swelling of the skin,
hives, redness of the skin, low blood pressure, fast heart rate and
sickness/vomiting/stomach cramp,<span style='color:black'> </span>or a
combination of such effects. If you notice any of these symptoms or signs,
inform your doctor or caregiver immediately.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Very common
side effects (may affect more than 1 in 10 people)</span></p>

<p class=CCDSMandatoryInformationbullet style='margin-left:28.1pt;text-indent:
-28.1pt;line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever</span></p>

<p class=CCDSMandatoryInformationbullet style='margin-left:0in;text-indent:
0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Common side
effects (may affect up to 1 in 10 people)</span></p>

<p class=CCDSMandatoryInformationbullet style='margin-left:28.1pt;text-indent:
-28.1pt;line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain (even if medicines are used to prevent or
lessen pain caused by the removal of burnt tissue)</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>-        Infection of the burn wound</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Complications of the wound including; wound
opening, wounds drying out and breaking down and failure of skin grafts to heal
properly</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you get any
side effects, talk to your doctor or nurse.</span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:red'> </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;background:lightgrey'>Appendix
V</span></a></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.       How </span></b><b><span lang=EN-GB>NexoBrid
is stored</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use
NexoBrid after the expiry date which is stated on the label of the vial,
bottle, and box after EXP. The expiry date refers to the last day of that
month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and
transport refrigerated (2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C&#8209;8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span
lang=EN-GB>C).</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in'><span lang=EN-GB>NexoBrid
must be stored upright to keep the gel at the bottom of the bottle and in the
original package to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>NexoBrid should be used within 15&nbsp;minutes after mixing the
powder with the gel.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These measures
will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>NexoBrid contains </span></b></p>

<p class=CCDSMandatoryInformationbullet style='margin-left:28.1pt;text-indent:
-28.1pt;line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance (in the powder in the vial)
is a concentrate of proteolytic enzymes enriched in bromelain: 5&nbsp;g,
corresponding to 0.09&nbsp;g/g concentrate of proteolytic enzymes enriched in
bromelain after mixing. The other ingredients are: for the powder ammonium
sulphate and acetic acid and for the gel carbomer 980, disodium phosphate
anhydrous, sodium hydroxide and water for infections.</span></p>

<p class=CCDSMandatoryInformationbullet style='margin-left:0in;text-indent:
0in;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>NexoBrid looks like and contents
of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>NexoBrid is provided as a powder and gel
for gel (powder in a vial (5&nbsp;g) and gel in a bottle (50&nbsp;g)), pack
size of 1 (a pack contains one vial of powder and one bottle of gel.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The powder is off-white to light tan and
the gel is clear and colourless.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>MediWound Germany
GmbH</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Eisenstrasse 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>65428 Rüsselsheim</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=DE>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=SV>Manufacturer</span><span
lang=SV>:</span></p>

<p class=NormalAgency><span lang=SV style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hälsa
Pharma GmbH</span></p>

<p class=NormalAgency><span lang=SV style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hafenweg
18-20</span></p>

<p class=NormalAgency><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>D-48155
Münster</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tél/Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal;layout-grid-mode:
  char'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Te&#1083;:
  +800 22232425</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>MediWound GmbH </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tél/Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:49.5pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>&#268;eská
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>MediWound GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=DE>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt;
  height:49.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Magyarország</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>Tel.: +800 22232425</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tlf: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>Tel: +800 22232425</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tlf: +800
  22232425</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&#932;&#951;&#955;: +2111990962</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Österreich</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>España</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>Tél: +800 22232425</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel.: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tél: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Portugal</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>Tel: </span><span lang=SV>+</span><span lang=EN-GB>15517564</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>România</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +40 0312295632</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  layout-grid-mode:line'><br clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: </span><span
  lang=SV>+800 22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Ísland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Sími: +800
  22232425</span></p>
  <p class=MsoNormal style='layout-grid-mode:char;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Slovenská
  republika</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>MediWound GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=SV>Tel: +800 22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=SV style='color:green'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Puh/Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#932;&#951;&#955;:
  +800 22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>MediWound
  GmbH</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Tel: +800
  22232425</span></p>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;layout-grid-mode:char'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><em><span
lang=EN-GB>&nbsp;</span></em></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in &lt;</span></b><span lang=EN-GB>{<b>MM/YYYY</b>}&gt;
&lt;</span><span lang=EN-GB>{<b>month YYYY</b>}<b>.</b>&gt;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: http://www.ema.europa.eu. There are also links to
other websites about rare diseases and treatments.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>---------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal'><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Preparation
and administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>From a
microbiological point of view and as the enzymatic activity of the product
decreases progressively following mixing, the reconstituted product should be
used immediately after preparation (within 15&nbsp;minutes).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>NexoBrid should be applied to a clean, keratin-free
(blisters removed), and moist wound area.</span></p>

<p class=MsoNormal style='margin-right:1.3pt;text-indent:.55pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Topically
applied medicinal products (such as silver sulfadiazine or povidone-iodine) at
the wound site must be removed and the wound must be cleansed prior to NexoBrid
application.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Preparation
of patient and wound area</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A total wound area of not more than
15%&nbsp;TBSA can be treated by NexoBrid.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain management must be used as commonly
practiced for an extensive dressing change; it should be initiated at least
15&nbsp;minutes prior to NexoBrid application.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must be cleaned thoroughly and the
superficial keratin layer or blisters removed from the wound area, as the
keratin will isolate the eschar from direct contact with NexoBrid and prevent
eschar removal by NexoBrid.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dressing soaked with an antibacterial solution
must be applied for 2&nbsp;hours.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>All topically applied antibacterial medicinal
products must be removed before applying NexoBrid. Remaining antibacterial
medicinal products may interfere with the activity of NexoBrid by decreasing
its efficacy.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The area from which you wish to remove the
eschar must be surrounded with a sterile paraffin ointment adhesive barrier by
applying it a few centimetres outside of the treatment area (using a
dispenser). The paraffin layer must not come into contact with the area to be
treated in order to avoid covering the eschar, thus isolating the eschar from
direct contact with NexoBrid.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>To prevent possible irritation of abraded skin by inadvertent
contact with NexoBrid</span><span lang=EN-GB> </span><span lang=EN-GB>and
possible bleeding from the wound bed, acute wound areas such as lacerations or
escharotomy incisions should be protected by a layer of a sterile fatty
ointment or fatty dressing (e.g. petrolatum gauze).</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Sterile isotonic sodium chloride 9&nbsp;mg/ml
(0.9%) solution must be sprinkled on the burn wound. The wound must be kept
moist during the application procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>NexoBrid gel
preparation (mixing powder with gel)</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The NexoBrid powder and gel are sterile. Aseptic
technique must be used when mixing NexoBrid powder with the gel. The powder
should not be inhaled.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The NexoBrid powder vial must be opened by
carefully tearing off the aluminium cap and removing the rubber stopper.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>When opening the gel bottle, it must be
confirmed that the tamper-evident ring is separating from the bottles cap. If
the tamper-evident ring was already separated from the cap before opening, the
gel bottle must be discarded and another, new gel bottle used.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>NexoBrid powder is then transferred into the
corresponding gel bottle. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>NexoBrid powder and gel must be mixed thoroughly
until a uniform, slightly tan to slightly brown mixture is obtained. This
usually requires mixing the NexoBrid powder and the gel for 1 to
2&nbsp;minutes.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>NexoBrid gel should be prepared at the patients
bedside.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>NexoBrid
application</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Within 15&nbsp;minutes of mixing, NexoBrid must
be applied topically to the burn wound, at a thickness of 1.5 to
3&nbsp;millimetres.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must then be covered with a sterile
occlusive film dressing that adheres to the sterile adhesive barrier material
applied as per the instruction above (see <i>Preparation of patient and wound
area</i>). The NexoBrid gel should fill the entire occlusive dressing, and
special care should be taken not to leave air under this occlusive dressing.
Gentle pressing of the occlusive dressing at the area of contact with the
adhesive barrier will ensure adherence between the occlusive film and the
barrier and achieve complete containment of NexoBrid on the treatment area.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dressed wound must be covered with a loose,
thick fluffy dressing, held in place with a bandage.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dressing must remain in place for
4&nbsp;hours.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Removal of
NexoBrid</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Appropriate preventive analgesia medicinal
products must be administered.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>After 4&nbsp;hours of NexoBrid treatment, the
occlusive dressing must be removed using aseptic techniques.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The adhesive barrier must be removed using a
sterile blunt-edged instrument (e.g., tongue depressor).</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The dissolved eschar must be removed from the
wound by wiping it away with a sterile blunt-edged instrument.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The wound must be wiped thoroughly first with a
large sterile dry gauze or napkin, followed by a sterile gauze or napkin that
has been soaked with sterile isotonic sodium chloride 9&nbsp;mg/ml (0.9%)
solution. The treated area must be rubbed until the appearance of a pinkish
surface with bleeding points or a whitish tissue. Rubbing will not remove
adhering undissolved eschar in areas where the eschar still remains.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A dressing soaked with an antibacterial solution
must be applied for an additional 2&nbsp;hours.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Wound care
after debridement</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The debrided area must be covered immediately by
temporary or permanent skin substitutes or dressings to prevent desiccation
and/or formation of pseudoeschar and/or infection.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Before a permanent skin cover or temporary skin
substitute is applied to a freshly enzymatically debrided area, a soaking
wet-to-dry dressing should be applied. </span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Before application of the grafts and primary
dressing, the debrided bed must be cleaned and refreshed by, e.g., brushing or
scraping to allow dressing adherence.</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Wounds with areas of full thickness and deep
burn should be autografted as soon as possible after NexoBrid debridement.
Careful consideration should also be given to placing permanent skin covers
(e.g. autografts) on deep partial thickness wounds soon after NexoBrid
debridement.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Recommendations
for safe handling</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each NexoBrid
vial, gel, or reconstituted gel should be used for a single patient only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are
reports of occupational exposure to bromelain leading to sensitisation.
Sensitisation may have occurred due to inhalation of bromelain powder. Allergic
reactions to bromelain </span><span lang=EN-GB>include anaphylactic reactions
and other immediate-type reactions with manifestations such as bronchospasm,
angiooedema, urticaria, and mucosal and gastrointestinal reactions. This should
be considered when mixing NexoBrid powder with the gel.. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Avoid accidental
eye exposure. In case of eye exposure, irrigate exposed eyes with copious
amounts of water for at least 15&nbsp;minutes. In case of skin exposure, rinse
NexoBrid off with water.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Disposal</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
product or waste material should be disposed of in accordance with local
requirements.</span></p>

</div>

</body>

</html>
